

CITATION REPORT

List of articles citing

A human homolog of angiotensin-converting enzyme.
Cloning and functional expression as a
captopril-insensitive carboxypeptidase

DOI: 10.1074/jbc.m002615200

Journal of Biological Chemistry, 2000, 275, 33238-43.

Source: <https://exaly.com/paper-pdf/32232657/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1644	The angiotensin system elements in invertebrates. 2001 , 36, 35-45		43
1643	A genomic perspective on human proteases. 2001 , 498, 214-8		36
1642	Angiotensin IV induces tyrosine phosphorylation of focal adhesion kinase and paxillin in proximal tubule cells. 2001 , 280, F980-8		34
1641	A genomic perspective on human proteases as drug targets. 2001 , 6, 681-688		83
1640	Bioactive angiotensin peptides: focus on angiotensin IV. 2001 , 2, 205-10		37
1639	Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. 2001 , 38, 660-4		55
1638	Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. <i>Journal of Biological Chemistry</i> , 2001 , 276, 17132-9	5.4	170
1637	ACEH/ACE2 is a novel mammalian metalloprotease and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. 2002 , 80, 346-53		131
1636	Angiotensin-converting enzyme 2--a new cardiac regulator. 2002 , 347, 1795-7		98
1635	Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. 2002 , 3, 195-204		58
1634	Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. 2002 , 124, 11852-3		133
1633	Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. 2002 , 8, 288-99		39
1632	Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. 2002 , 39, 976-81		108
1631	Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. 2002 , 532, 107-10		550
1630	Metabolism of angiotensin I in the coronary circulation of normal and diabetic rats. 2002 , 23, 1171-5		10
1629	The angiotensin-converting enzyme gene family: genomics and pharmacology. 2002 , 23, 177-83		311
1628	Formation of angiotensin-(1-7) from angiotensin II by the venom of <i>Conus geographus</i> . 2002 , 105, 101-8		2

1627	Just the beginning: novel functions for angiotensin-converting enzymes. 2002 , 12, R745-52		106
1626	High-performance liquid chromatographic separation of renin-angiotensin system peptides and most of their metabolic fragments. 2002 , 780, 301-7		5
1625	Angiotensin-converting enzyme 2 is an essential regulator of heart function. 2002 , 417, 822-8		1345
1624	Two ACEs and a heart. 2002 , 417, 799-802		34
1623	Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. <i>Journal of Biological Chemistry</i> , 2002 , 277, 14838-43	5-4	1012
1622	X=Y=ZH Systems as potential 1,3-dipoles. Part 58: Cycloaddition route to chiral conformationally constrained (R)-pro-(S)-pro peptidomimetics. 2003 , 59, 8481-8487		16
1621	Angiotensin converting enzyme-2 (ACE2) and its possible roles in hypertension, diabetes and cardiac function. 2003 , 10, 377-385		9
1620	A story of two ACEs. 2003 , 81, 227-34		58
1619	The role of ACE2 in cardiovascular physiology. 2003 , 13, 93-101		182
1618	Target validation using human tissue: from gene expression to function. 2003 , 2, 58-64		4
1617	Development of intramolecularly quenched fluorescent peptides as substrates of angiotensin-converting enzyme 2. 2003 , 312, 141-7		18
1616	Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumours. 2003 , 111, 234-43; discussion 243-4		16
1615	Abrogation of E-cadherin-mediated adhesion induces tumor cell invasion in human skin-like organotypic culture. 2003 , 121, 1182-90		15
1614	An ACE structure. 2003 , 10, 155-7		25
1613	Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. 2003 , 426, 450-4		3969
1612	Hypothesis: ACE2 modulates blood pressure in the mammalian organism. 2003 , 41, 871-3		99
1611	Localization of carboxypeptidase A-like enzyme in rat kidney. 2003 , 24, 1237-40		8
1610	Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function. 2003 , 10, 377-385		9

1609	Crystal structure of <i>Drosophila</i> angiotensin I-converting enzyme bound to captopril and lisinopril. 2003 , 538, 65-70		84
1608	Structure of human ACE gives new insights into inhibitor binding and design. 2003 , 24, 391-4		25
1607	The renin-angiotensin and the kallikrein-kinin systems. 2003 , 35, 784-91		110
1606	Inflammation and angiotensin II. 2003 , 35, 881-900		524
1605	The intrarenal renin-angiotensin system and diabetic nephropathy. 2003 , 14, 274-81		176
1604	An essential role in molting and morphogenesis of <i>Caenorhabditis elegans</i> for ACN-1, a novel member of the angiotensin-converting enzyme family that lacks a metallopeptidase active site. <i>Journal of Biological Chemistry</i> , 2003 , 278, 52340-6	5-4	55
1603	Angiotensin-I-converting enzyme and its relatives. 2003 , 4, 225		164
1602	Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. 2003 , 42, 13185-92		132
1601	Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. 2003 , 108, 1707-12		273
1600	Do studies with ACE N- and C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway?. 2003 , 93, 91-3		11
1599	Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. 2003 , 108, 2141-6		114
1598	Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. 2003 , 108, 1679-81		105
1597	Novel peptide inhibitors of angiotensin-converting enzyme 2. <i>Journal of Biological Chemistry</i> , 2003 , 278, 15532-40	5-4	150
1596	Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. 2003 , 42, 749-53		112
1595	Demographics, treatment regimens and the use of angiotensin-receptor blockers in heart failure: findings from the Valsartan Heart Failure Trial. 2003 , 31, 351-61		2
1594	Commentary on Tikellis et al: There is more to discover about angiotensin-converting enzyme. 2003 , 41, 390-1		24
1593	Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. 2003 , 41, 392-7		307
1592	Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. 2003 , 14, 873-80		125

1591	The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. 2003 , 285, R1-13	122
1590	Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. 2003 , 24, 261-71	445
1589	Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. 2003 , 284, H1985-94	146
1588	Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. 2003 , 371, 437-42	55
1587	Hypertension and Angiotensin II Hypersensitivity in Aminopeptidase A-deficient Mice. 2003 , 9, 57-62	49
1586	[A second angiotensin-converting enzyme for the heart?]. 2003 , 19, 141-3	0
1585	Prologue: kinins and related systems. New life for old discoveries. 2003 , 284, H1886-91	16
1584	Our fragmentary knowledge of the regulatory functions of ANG II "fragments": are we beginning to see the light?. 2003 , 285, R937-8	0
1583	Enhanced expression of Ang-(1-7) during pregnancy. 2004 , 37, 1255-62	85
1582	Angiotensin-converting enzyme 2. 2004 , 349-351	8
1581	ACE, ACE inhibitors, and other JNK. 2004 , 94, 1-3	57
1580	ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. <i>Journal of Biological Chemistry</i> , 2004 , 279, 17996-8007	5-4 424
1579	Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. 2004 , 5, 203-8	59
1578	Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. 2004 , 43, 1120-5	183
1577	Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart. 2004 , 43, 943-4	11
1576	Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. 2004 , 383, 45-51	462
1575	ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. 2004 , 50, 1683-6	65
1574	Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes. 2004 , 239, 47-97	27

1573	Review: The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. 2004 , 10, 3-13	2
1572	ACE2 gene expression is up-regulated in the human failing heart. 2004 , 2, 19	167
1571	Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [¹²⁵ I]Ang IV binding and catalytic activity. 2004 , 68, 885-92	41
1570	Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. 2004 , 6, 117-23	10
1569	Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. 2004 , 6, 124-8	13
1568	Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. 2004 , 203, 631-7	3418
1567	Renal ACE2 expression in human kidney disease. 2004 , 204, 587-93	190
1566	Identification of angiotensin converting enzyme 2 in the rodent retina. 2004 , 29, 419-27	64
1565	Interaction of ACE2 and integrin beta1 in failing human heart. 2004 , 1689, 175-8	29
1564	Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. 2004 , 319, 1216-21	208
1563	ACE2, a new regulator of the renin-angiotensin system. 2004 , 15, 166-9	230
1562	Cellular entry of the SARS coronavirus. 2004 , 12, 466-72	172
1561	ACE2: from vasopeptidase to SARS virus receptor. 2004 , 25, 291-4	370
1560	Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. 2004 , 89-90, 387-92	388
1559	No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. 2004 , 17, 624-8	58
1558	A model of the ACE2 structure and function as a SARS-CoV receptor. 2004 , 314, 235-41	128
1557	Valsartan. 2004 , 2, 67-101	2
1556	Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. 2004 , 22, 1971-6	64

1555	Characterization of the first non-insect invertebrate functional angiotensin-converting enzyme (ACE): leech TtACE resembles the N-domain of mammalian ACE. 2004 , 382, 565-73	17
1554	Role of aminopeptidases in the blood pressure regulation. 2004 , 27, 768-71	20
1553	Peptides and the enzymes that release or inactivate them: A short history of my life and work entwined. 2004 , 279-354	2
1552	New fACEs to the renin-angiotensin system. 2005 , 20, 91-5	36
1551	Renin-angiotensin system intervention to prevent in-stent restenosis: an unclosed chapter. 2005 , 45, 88-98	15
1550	Myocardial infarction increases ACE2 expression in rat and humans. 2005 , 26, 369-75; discussion 322-4	324
1549	The renin-angiotensin system: peptides and enzymes beyond angiotensin II. 2005 , 14, 155-9	54
1548	Membrane-associated zinc peptidase families: comparing ACE and ACE2. 2005 , 1751, 2-8	64
1547	Angiotensin-Converting Enzymes: Properties and Function. 2005 , 95-99	
1546	A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. 2005 , 11, 875-9	2294
1545	Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. 2005 , 90, 299-305	30
1544	Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. 2005 , 90, 783-90	186
1543	Angiotensin-converting enzyme 2 protects from severe acute lung failure. 2005 , 436, 112-6	1770
1542	Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. 2005 , 272, 3512-20	74
1541	Cardiovascular effects of angiotensin II and angiotensin-(1-7) at the RVLM of trained normotensive rats. 2005 , 1040, 121-8	33
1540	Identification of an alternative 5'-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: lack of association with SARS in the Vietnamese population. 2005 , 136, 52-7	40
1539	Rethinking the renin-angiotensin system and its role in cardiovascular regulation. 2005 , 19, 77-87	47
1538	Angiotensin-(1-7). 2005 , 100-110	6

1537	A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. 2005 , 288, F1183-90	73
1536	Cardiovascular actions of angiotensin-(1-7). 2005 , 38, 499-507	126
1535	The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. 2005 , 288, F353-62	110
1534	Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. 2005 , 289, H2356-63	185
1533	Angiotensin II and the endothelium: diverse signals and effects. 2005 , 45, 163-9	173
1532	ACE and ACE2: a tale of two enzymes. 2005 , 26, 322-4	82
1531	Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension?. 2005 , 46, 1097-9	32
1530	Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). <i>Journal of Biological Chemistry</i> , 2005 , 280, 30113-9	5-4 467
1529	Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. 2005 , 45, 138-41	90
1528	Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. 2005 , 54, 1790-6	215
1527	Losartan increases bradykinin levels in hypertensive humans. 2005 , 111, 315-20	141
1526	Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. 2005 , 111, 2605-10	1135
1525	Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. <i>Journal of Biological Chemistry</i> , 2005 , 280, 39353-62	5-4 134
1524	Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors. 2005 , 6, 96-101	13
1523	Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. 2005 , 46, 953-9	34
1522	Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. 2005 , 46, 937-42	145
1521	Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. 2005 , 46, 1169-74	91
1520	Crystal structure of the E. coli dipeptidyl carboxypeptidase Dcp: further indication of a ligand-dependent hinge movement mechanism. 2005 , 349, 99-112	35

1519	Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. 2005 , 29, 427-35	92
1518	Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. 2005 , 37, 1357-67	75
1517	Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. 2005 , 26, 1270-7	151
1516	Role of PGI2 and effects of ACE inhibition on the bradykinin potentiation by angiotensin-(1-7) in resistance vessels of SHR. 2005 , 127, 183-9	14
1515	Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. 2005 , 2, 69	1148
1514	ACE polymorphisms. 2006 , 98, 1123-33	314
1513	Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. 2006 , 46, 708-16	75
1512	Identification of new participants in the rainbow trout (<i>Oncorhynchus mykiss</i>) oocyte maturation and ovulation processes using cDNA microarrays. 2006 , 4, 39	91
1511	Angiotensin, bradykinin and the endothelium. 2006 , 255-94	13
1510	The renin-angiotensin system in acute respiratory distress syndrome. 2006 , 3, 225-229	21
1509	Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. 2007 , 41, 183-196	27
1508	Localization of angiotensin II, the AT1 receptor, angiotensin-converting enzyme, aminopeptidase A, adipocyte-derived leucine aminopeptidase, and vascular endothelial growth factor in the human ovary throughout the menstrual cycle. 2006 , 86, 433-9	29
1507	Venom gland EST analysis of the saw-scaled viper, <i>Echis ocellatus</i> , reveals novel alpha9beta1 integrin-binding motifs in venom metalloproteinases and a new group of putative toxins, renin-like aspartic proteases. 2006 , 377, 21-32	86
1506	ACE2 orthologues in non-mammalian vertebrates (<i>Danio</i> , <i>Gallus</i> , <i>Fugu</i> , <i>Tetraodon</i> and <i>Xenopus</i>). 2006 , 377, 46-55	23
1505	Angiotensin-converting enzyme 2 in lung diseases. 2006 , 6, 271-6	272
1504	Analysis of the mechanisms underlying the vasorelaxant action of angiotensin II in the isolated rat carotid. 2006 , 78, 2676-82	15
1503	Alterations in aortic vascular reactivity to angiotensin 1-7 in 17-beta-estradiol-treated female SD rats. 2006 , 133, 62-7	8
1502	Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. 2006 , 111, 333-40	45

1501	The tissue renin-angiotensin system and intracellular signalling. 2006 , 15, 8-13	47
1500	Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). 2006 , 16, 43-95	15
1499	Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. 2006 , 24, 239-46	56
1498	Structural diversity of angiotensin-converting enzyme. 2006 , 273, 362-73	16
1497	Testicular isoform of angiotensin I-converting enzyme (ACE, CD143) on the surface of human spermatozoa: revelation and quantification using monoclonal antibodies. 2006 , 55, 54-68	26
1496	ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7). 2006 , 70, 8-10	55
1495	Developmental expression of ACE2 in the SHR kidney: a role in hypertension?. 2006 , 70, 34-41	63
1494	Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. 2006 , 64, 6-12	88
1493	Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. 2006 , 69, 2212-8	153
1492	Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. 2006 , 29, 865-74	105
1491	Characterization of Angiotensin Converting Enzyme-2 (ACE2) in Human Urine. 2006 , 12, 283-289	17
1490	Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. 2006 , 84, 88-96	78
1489	Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. 2006 , 84, 814-20	105
1488	Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 2006 , 350, 15-25	138
1487	Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. 2006 , 147, 91-5	52
1486	ACE2: A novel therapeutic target for cardiovascular diseases. 2006 , 91, 163-98	70
1485	Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. 2006 , 27, 200-7	162
1484	Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. 2006 , 26, 414-33	22

1483	Potential of gene therapy strategy for the treatment of hypertension. 2006 , 47, 6-9	21
1482	Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease. 2006 , 60, 734-9	48
1481	Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. 2006 , 2, 335-42	13
1480	Association analysis of common variants of ELN, NOS2A, APOE and ACE2 to intracranial aneurysm. 2006 , 37, 1189-94	34
1479	Angiotensin-Converting Enzyme-2 (ACE2) A New Player in the Genesis of Glomerular Injury?. 2006 , 17, 2637-2643	
1478	Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. 2006 , 290, C420-6	146
1477	Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. 2006 , 34, 272-83	64
1476	Orchitis: a complication of severe acute respiratory syndrome (SARS). 2006 , 74, 410-6	250
1475	Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. 2006 , 80, 4211-9	206
1474	New mass spectrometric assay for angiotensin-converting enzyme 2 activity. 2006 , 47, 1010-7	60
1473	ACE2: a new target for prevention of diabetic nephropathy?. 2006 , 17, 2957-9	23
1472	ACE and ACE2 activity in diabetic mice. 2006 , 55, 2132-9	240
1471	Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. 2006 , 48, 914-20	135
1470	Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. 2006 , 47, 718-26	264
1469	Intratubular Renin-Angiotensin System in Hypertension. 2006 , 2, 151-157	6
1468	Physiology of local renin-angiotensin systems. 2006 , 86, 747-803	1225
1467	7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. 2006 , 80, 785-93	118
1466	Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. 2006 , 48, 572-8	213

1465	Angiotensin-converting enzyme II in the heart and the kidney. 2006 , 98, 463-71	195
1464	ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. 2007 , 72, 614-23	166
1463	A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. 2007 , 104, 11424-9	164
1462	Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. 2007 , 58, 710-6	12
1461	Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. 2007 , 293, R169-77	67
1460	Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. 2007 , 50, 762-7	38
1459	Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. 2007 , 292, F82-91	115
1458	Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study. 2007 , 9, 602-9	69
1457	Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. 2007 , 9, 594-601	18
1456	Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. 2007 , 101, e32-42	219
1455	The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. 2007 , 292, H1113-9	96
1454	ACE2: a new target for cardiovascular disease therapeutics. 2007 , 50, 112-9	132
1453	Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. 2007 , 292, R373-81	280
1452	Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. 2007 , 148, 2453-7	89
1451	Angiotensin-converting enzyme and vascular remodeling. 2007 , 101, 441-54	158
1450	Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. 2007 , 293, H1416-24	123
1449	Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. 2007 , 8, 74-80	47
1448	Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus. 2007 , 8, 34-41	22

1447	Angiotensin-(1-7) and the renin-angiotensin system. 2007 , 16, 122-8	126
1446	The emerging role of angiotensin-converting enzyme-2 in the kidney. 2007 , 16, 116-21	29
1445	Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. 2007 , 143, 15-27	64
1444	Virus-mediated modulation of the host endocrine signaling systems: clinical implications. 2007 , 18, 159-66	10
1443	Evidence for an angiotensin-converting enzyme (ACE) polymorphism in the crayfish <i>Astacus leptodactylus</i> . 2007 , 28, 1368-74	2
1442	Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active. 2007 , 399, 81-90	24
1441	Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. 2007 , 47, 387-95	122
1440	Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. 2007 , 81, 916-23	49
1439	Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. 2007 , 581, 526-34	37
1438	The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. 2007 , 59, 251-87	930
1437	The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure. 2007 , 87, 565-92	74
1436	The renin-angiotensin system and diabetic nephropathy. 2007 , 27, 144-52	96
1435	Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). 2007 , 292, H736-42	281
1434	New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. 2007 , 82, 113-35	56
1433	Retinoic acid and the heart. 2007 , 75, 257-83	65
1432	Oxidative damage pathways in relation to normal tissue injury. 2007 , 80 Spec No 1, S23-31	139
1431	Liver fibrosis: a balance of ACEs?. 2007 , 113, 109-18	85
1430	Angiotensin I-Converting Enzyme (ACE). 2007 , 1-7	

1429	The Renin-Angiotensin System in the Pathophysiology of Essential Hypertension. 2007 , 299-315	
1428	Pathophysiology of Hypertension. 2007 , 25-46	3
1427	Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. 2007 , 101, 1278-91	66
1426	Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues. 2007 , 79, 1245-53	31
1425	The emerging role of ACE2 in physiology and disease. 2007 , 212, 1-11	282
1424	Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. 2007 , 82, 187-96	78
1423	Effect of enalapril treatment on the sensitivity of cardiopulmonary reflexes in rats with myocardial infarction. 2007 , 34, 606-11	8
1422	Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. 2007 , 25, 162-74	89
1421	Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. 2007 , 8, 194	21
1420	Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. 2008 , 58, 119-26	4
1419	Angiotensin metabolites can stimulate receptors of the Mas-related genes family. 2008 , 319, 115-23	61
1418	Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. 2008 , 13, 321-37	79
1417	Brain renin angiotensin in disease. 2008 , 86, 715-22	145
1416	Update on tissue renin-angiotensin systems. 2008 , 86, 615-21	204
1415	Are we poised to target ACE2 for the next generation of antihypertensives?. 2008 , 86, 685-90	23
1414	Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. 2008 , 51, 1062-7	42
1413	Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease. 2008 , 10, 70-7	16
1412	Angiotensin-(1-7) as an antihypertensive, antifibrotic target. 2008 , 10, 227-32	32

1411	Pharmacologic modulation of ACE2 expression. 2008 , 10, 410-4	50
1410	Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. 2008 , 34, 56-61	76
1409	Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. 2008 , 215, 273-9	82
1408	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. 2008 , 18, 732-7	17
1407	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. 2008 , 18, 1681-7	5
1406	Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. 2008 , 51, 2216-26	43
1405	Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. 2008 , 29, 829-37	61
1404	Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. 2008 , 275, 6033-42	27
1403	Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. 2008 , 93, 538-42	52
1402	The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. 2008 , 93, 543-8	219
1401	Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts. 2008 , 93, 579-88	30
1400	Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34-positive cells in rabbit atherosclerotic plaques. 2008 , 93, 564-9	16
1399	Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. 2008 , 93, 613-21	48
1398	Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. 2008 , 93, 665-75	36
1397	Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. 2008 , 93, 685-93	94
1396	Angiotensin-converting enzyme 2 and the kidney. 2008 , 93, 549-56	30
1395	RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2. 2008 , 93, 676-84	28
1394	Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. 2008 , 93, 519-27	328

1393	Angiotensin-converting enzyme 2 in the brain: properties and future directions. 2008 , 107, 1482-94	222
1392	Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. 2008 , 23, 1327-38	88
1391	Angiotensin converting enzyme 2 in the kidney. 2008 , 35, 420-5	33
1390	Renin-angiotensin system revisited. 2008 , 264, 224-36	394
1389	Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems. 2008 , 20, 279-89	16
1388	An immunosuppressed Syrian golden hamster model for SARS-CoV infection. 2008 , 380, 312-21	59
1387	ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages. 2008 , 39, 149-54	32
1386	Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. 2008 , 582, 385-90	96
1385	Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. 2008 , 75, 781-6	80
1384	Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. 2008 , 585, 303-12	101
1383	Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. 2008 , 51, 613-23	154
1382	AT2 receptors: functional relevance in cardiovascular disease. 2008 , 120, 292-316	195
1381	[Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system]. 2008 , 131, 230-6	17
1380	Pathophysiology of Primary Hypertension. 2008 , 794-895	1
1379	An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. 2008 , 52, 755-7	13
1378	Renin-angiotensin system blockade in diabetic nephropathy. 2008 , 2, 135-158	1
1377	Vascular biology of angiotensin and the impact of physical activity. 2008 , 33, 162-72	47
1376	Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. 2008 , 156, 752-8	19

1375	Angiotensin processing is partially carried out by carboxypeptidases in the rat mesenteric arterial bed perfusate. 2008 , 151, 135-8	6
1374	Functional genetic variation in aminopeptidase A (ENPEP): lack of clear association with focal and segmental glomerulosclerosis (FSGS). 2008 , 410, 44-52	6
1373	[Structure and function of angiotensin converting enzyme and its inhibitors]. 2008 , 24, 171-6	18
1372	Does the renin-angiotensin system also regulate intra-ocular pressure?. 2008 , 40, 418-27	31
1371	Expression of novel genes encoded by the paramyxovirus J virus. 2008 , 89, 1434-1441	11
1370	Pathophysiology of Primary Hypertension. 2008 , 794-895	3
1369	A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. 2008 , 29, 133-54	144
1368	Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. 2008 , 31, 1953-61	33
1367	Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. 2008 , 105, 7809-14	367
1366	Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. 2008 , 51, 1312-7	207
1365	Angiotensin-converting enzyme 2: cardioprotective player in the renin-angiotensin system?. 2008 , 52, 816-7	7
1364	ACE2 and ANG-(1-7) in the gravid uterus: the new players on the block. 2008 , 294, R915-6	5
1363	Regulation of ACE2 in cardiac myocytes and fibroblasts. 2008 , 295, H2373-9	175
1362	ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. 2008 , 295, R781-8	135
1361	The angiotensin converting enzyme 2/Ang-(1-7) axis in the heart: a role for MAS communication?. 2008 , 103, 1197-9	21
1360	Cardiovascular protection by angiotensin-converting enzyme 2: a new paradigm. 2008 , 4, 175-82	4
1359	Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. 2008 , 103, 1319-26	188
1358	Angiotensin II relaxations of bovine adrenal cortical arteries: role of angiotensin II metabolites and endothelial nitric oxide. 2008 , 52, 150-5	13

- 1357 New insight of angiotensin II receptor blocker treatment in cardiac dysfunction using angiotensin-converting enzyme 2-deficient mice. **2008**, 31, 1833-4
- 1356 Sex differences in response to chronic heart failure therapies. **2008**, 6, 555-65 15
- 1355 Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. **2008**, 72, 1346-50 40
- 1354 Physiologie et méthodes d'exploration du système rénine-angiotensine-aldostérone. **2008**, 5, 1-10 1
- 1353 New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. **2008**, 17, 250-7 26
- 1352 Targeting genes in the renin-angiotensin system. **2008**, 17, 57-63 17
- 1351 Cardiorenal Physiology of the Mouse: From Loss of Genome to Gain of Phenome. **2008**, 15-39
- 1350 Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes. Focus on Ramipril. **2009**, 1, CMT.S2095
- 1349 Renin-angiotensin system in the pathogenesis of liver fibrosis. **2009**, 15, 2579-86 57
- 1348 Physiological and pathophysiological roles of placental aminopeptidase in maternal sera: possible relation to preeclampsia and preterm delivery. **2009**, 3, 479-91 3
- 1347 Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. **2009**, 297, H1557-66 78
- 1346 Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. **2009**, 24, 1766-73 68
- 1345 The role of ACE2 in pulmonary diseases--relevance for the nephrologist. **2009**, 24, 1362-5 23
- 1344 The identification of a calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2. **2009**, 150, 2376-81 26
- 1343 Losartan chemistry and its effects via AT1 mechanisms in the kidney. **2009**, 16, 3701-15 21
- 1342 Cardiovascular effects of losartan and its relevant clinical application. **2009**, 16, 3841-57 21
- 1341 Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. **2009**, 297, L84-96 222
- 1340 High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs. **2009**, 296, H106-18 41

1339	Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. 2009 , 297, C1318-29	50
1338	Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. 2009 , 297, G98-G106	29
1337	Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. 2009 , 297, L631-40	151
1336	The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. 2009 , 2009, 752406	65
1335	Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. 2009 , 296, F337-46	71
1334	Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. 2009 , 3, 103-11	21
1333	Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. 2009 , 2, 446-55	173
1332	Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. 2009 , 53, 694-700	36
1331	Angiotensin II signaling and its implication in erectile dysfunction. 2009 , 6 Suppl 3, 302-10	36
1330	The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. 2009 , 78, 933-40	48
1329	Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. 2009 , 50, 929-38	100
1328	Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. 2009 , 58, 819-27	44
1327	Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients. 2009 , 30, 1237-44	20
1326	The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats. 2009 , 214, 736-43	44
1325	Regulation of renin release by local and systemic factors. 2011 , 161, 1-44	20
1324	Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. 2009 , 32, 533-6	202
1323	Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter. 2009 , 164, 1263-73	17
1322	Acute modulation of myocardial function by angiotensin 1-7. 2009 , 30, 1714-9	8

1321	Seven decades of angiotensin (1939-2009). 2009 , 30, 1945-50	36
1320	The sweeter side of ACE2: physiological evidence for a role in diabetes. 2009 , 302, 193-202	155
1319	Intrarenal renin-angiotensin system. 2009 , 302, 185-92	13
1318	Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. 2009 , 136, 872-82	186
1317	Physiology and Regulation of the Renin-Angiotensin-Aldosterone System. 2009 , 147-165	
1316	Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. 2009 , 75, 1184-1193	113
1315	The vasoactive peptide angiotensin-(1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium. 2009 , 16, 247-56	79
1314	La mđula renal normal y patolđica. 2009 , 42, 263-275	
1313	Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. 2009 , 18, 79-84	53
1312	Linking diabetes and atherosclerosis. 2009 , 4, 603-624	6
1311	Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 2009 , 117, 375-86	79
1310	Endogenous Vasoactive Peptides. 2010 , 515-566	
1309	Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. 2010 , 28, 1054-64	65
1308	Brain angiotensin peptides regulate sympathetic tone and blood pressure. 2010 , 28, 1599-610	50
1307	Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. 2010 , 38, 596-601	84
1306	Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats. 2010 , 43, 837-42	24
1305	Renin-angiotensin system in human coronavirus pathogenesis. 2010 , 5, 145-161	40
1304	Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. 2010 , 118, 269-79	47

1303	ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. 2010 , 119, 385-94	75
1302	Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. 2010 , 74, 405-10	123
1301	Not just angiotensinases: new roles for the angiotensin-converting enzymes. 2010 , 67, 89-98	69
1300	Angiotensin-(1-7) and angiotensin II in the rostral ventrolateral medulla modulate the cardiac sympathetic afferent reflex and sympathetic activity in rats. 2010 , 459, 681-8	45
1299	Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. 2010 , 47, 193-9	589
1298	Angiotensin-converting enzyme 2: central regulator for cardiovascular function. 2010 , 12, 170-5	94
1297	Diagnosis and treatment of heart disease: are women different from men?. 2010 , 53, 227-36	66
1296	Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. 2010 , 128, 119-28	295
1295	The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. 2010 , 29, 284-311	106
1294	Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. 2010 , 165, 218-23	19
1293	Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. 2010 , 10, 134	64
1292	TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. 2010 , 85, 551-5	92
1291	Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. 2010 , 15, 332-41	54
1290	The crosstalk between thyroid hormones and the Renin-Angiotensin System. 2010 , 52, 166-70	38
1289	Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17 β estradiol-dependent and sex chromosome-independent. 2010 , 1, 6	169
1288	Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. 2010 , 95, 601-6	37
1287	The renin-angiotensin system and cancer: old dog, new tricks. 2010 , 10, 745-59	341
1286	Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. 2010 , 37, e1-6	63

1285	Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. 2010 , 122, 717-28, 18 p following 728	341
1284	Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. 2010 , 84, 7703-12	81
1283	Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. 2010 , 56, 112-20	86
1282	Simultaneous administration of Ang(1-7) or A-779 does not affect the chronic hypertensive effects of angiotensin II in normal rats. 2010 , 11, 99-102	11
1281	Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. 2010 , 30, 1606-13	124
1280	European Perspectives. 2010 , 121,	
1279	Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. 2010 , 107, 888-97	179
1278	Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. 2010 , 185, 5569-76	130
1277	Human recombinant ACE2 reduces the progression of diabetic nephropathy. 2010 , 59, 529-38	234
1276	Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. 2010 , 59, 2540-8	151
1275	The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. 2010 , 298, F1297-305	113
1274	The highly cited SARS research literature. 2010 , 36, 299-317	11
1273	Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. 2010 , 38, 558-69	24
1272	Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. 2010 , 298, F1523-32	89
1271	Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. 2010 , 299, G70-80	17
1270	Inhibitory effects of angiotensin-(1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed. 2010 , 298, H457-65	18
1269	Confirmation that the renin gene distal enhancer polymorphism REN-5312C/T is associated with increased blood pressure. 2010 , 3, 53-9	14
1268	Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. 2010 , 31, 541-50	171

1267	Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. 2010 , 55, 90-8	226
1266	Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27. 2010 , 33, 123-8	14
1265	Do angiotensin II type 1 receptor blockers have molecular effects?. 2010 , 33, 105-6	6
1264	Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). 2010 , 59, 197-233	51
1263	New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. 2010 , 14, 485-96	23
1262	Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. 2010 , 33, 118-22	28
1261	Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. 2010 , 33, 298-307	43
1260	Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. 2010 , 145, 333-334	36
1259	Effects of ACE2 inhibition in the post-myocardial infarction heart. 2010 , 16, 777-85	35
1258	Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. 2010 , 31, 1334-40	19
1257	Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. 2010 , 162, 73-8	27
1256	Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. 2010 , 50, 439-65	240
1255	The renin angiotensin system and the metabolic syndrome. 2010 , 100, 525-34	133
1254	Physiology of kidney renin. 2010 , 90, 607-73	188
1253	A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. 2011 , 85, 873-82	460
1252	ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. 2011 , 34, 154-60	117
1251	Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR- δ agonist action. 2011 , 45, 575-84	66
1250	Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy. 2011 , 5, 159-67	23

1249	The role of the renin-angiotensin system in liver fibrosis. 2011 , 236, 557-66	45
1248	ACE2, a promising therapeutic target for pulmonary hypertension. 2011 , 11, 150-5	79
1247	Purification and characterization of angiotensin converting enzyme 2 (ACE2) from murine model of mesangial cell in culture. 2011 , 49, 79-84	15
1246	A new approach regarding the treatment of preeclampsia and preterm labor. 2011 , 88, 17-23	9
1245	Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. 2011 , 51, 542-7	51
1244	New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. 2011 , 32, 1551-65	108
1243	Identifying the regulatory element for human angiotensin-converting enzyme 2 (ACE2) expression in human cardiofibroblasts. 2011 , 32, 1832-9	23
1242	Regulation of Angiotensin II receptor signaling by cysteine modification of NF- κ B. 2011 , 25, 112-7	21
1241	ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. 2011 , 300, R804-17	194
1240	Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. 2011 , 57, 314-22	183
1239	Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. 2011 , 50, 5182-94	33
1238	Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. 2011 , 17, 59-69	91
1237	ACE2 and Angiotensin-(1-7) in Hypertensive Renal Disease. 2011 , 9, 41-4	8
1236	Alternative pathways for angiotensin II generation in the cardiovascular system. 2011 , 44, 914-9	29
1235	ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. 2011 , 6, e22682	86
1234	A crucial role in fertility for the oyster angiotensin-converting enzyme orthologue CgACE. 2011 , 6, e27833	13
1233	Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. 2011 , 29, 706-15	47
1232	Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. 2011 , 29, 2236-45	24

1231	Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. 2011 , 20, 62-8	108
1230	Urinary angiotensin-converting enzyme 2 in patients with CKD. 2011 , 16, 567-72	43
1229	Review article: pancreatic renin-angiotensin systems in health and disease. 2011 , 34, 840-52	32
1228	Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. 2011 , 96, 287-94	90
1227	Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. 2011 , 96, 1084-96	142
1226	Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. 2011 , 301, R1293-9	48
1225	Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart. 2011 , 34, 609-13	23
1224	Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations. 2011 , 25, 87-97	7
1223	Enhanced angiotensin-converting enzyme 2 attenuates angiotensin II-induced collagen production via AT1 receptor-phosphoinositide 3-kinase-Akt pathway. 2011 , 39, 139-47	9
1222	Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. 2011 , 8, 176-83	54
1221	Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. 2011 , 225, 618-27	232
1220	EAmino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2). 2011 , 24, 235-44	5
1219	A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project. 2011 , 12, 504-9	18
1218	Angiotensin peptides and lung cancer. 2011 , 11, 394-404	40
1217	Gene transfer of angiotensin-converting enzyme 2 in the nucleus tractus solitarius improves baroreceptor heart rate reflex in spontaneously hypertensive rats. 2011 , 12, 456-61	23
1216	Renin-angiotensin system may trigger kidney damage in NOD mice. 2011 , 12, 15-22	14
1215	The Conformation and Assignment of the Proton NMR Spectrum in Water of DX600, a Bioactive Peptide with a Random Coil Conformation. 2011 , 2011, 1-8	1
1214	Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. 2011 , 2011, 521076	45

1213	Prediction of off-target effects on angiotensin-converting enzyme 2. 2011 , 16, 878-85	82
1212	Rat Ace allele variation determines susceptibility to AngII-induced renal damage. 2011 , 12, 420-9	2
1211	The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatrial node cells of rats. 2011 , 59, 761-8	28
1210	Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. 2011 , 24, 89-101	21
1209	Placental leucine aminopeptidase- and aminopeptidase A- deficient mice offer insight concerning the mechanisms underlying preterm labor and preeclampsia. 2011 , 2011, 286947	11
1208	Role of angiotensin-(1-7) in rostral ventrolateral medulla in blood pressure regulation via sympathetic nerve activity in Wistar-Kyoto and spontaneous hypertensive rats. 2011 , 33, 223-30	18
1207	Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. 2011 , 120, 335-45	58
1206	Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. 2011 , 121, 297-303	209
1205	Angiotensin-converting enzyme 2 overexpression improves central nitric oxide-mediated sympathetic outflow in chronic heart failure. 2011 , 301, H2402-12	32
1204	Vitamin D and the Renin-Angiotensin System. 2011 , 707-723	
1203	Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport. 2012 , 303, E669-81	33
1202	Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. 2012 , 302, F840-52	51
1201	Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling. 2012 , 2012, 594361	39
1200	Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. 2012 , 302, E1016-24	52
1199	Angiotensin-(1-7)-mediated signaling in cardiomyocytes. 2012 , 2012, 493129	34
1198	The arterial depressor response to chronic low-dose angiotensin II infusion in female rats is estrogen dependent. 2012 , 302, R159-65	50
1197	Angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor axis and related mechanisms. 2012 , 2012, 690785	12
1196	Angiotensin-(1-7) in kidney disease: a review of the controversies. 2012 , 123, 333-46	75

1195	Lack of Association of ACE2 G8790A Gene Mutation with Essential Hypertension in the Chinese Population: A Meta-Analysis Involving 5260 Subjects. 2012 , 3, 364	10
1194	Targeting proteases in cardiovascular diseases by mass spectrometry-based proteomics. 2012 , 5, 265	5
1193	Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. 2012 , 302, F784-90	48
1192	Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. 2012 , 2012, 192567	31
1191	Biosynthetic pathways and the role of the MAS receptor in the effects of Angiotensin-(1-7) in smooth muscles. 2012 , 2012, 121740	5
1190	Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. 2012 , 2012, 256294	350
1189	Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. 2012 , 93, 1924-1929	110
1188	Ontogeny of angiotensin-converting enzyme 2. 2012 , 71, 13-9	38
1187	Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. 2012 , 82, 292-303	88
1186	Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. <i>Journal of Biological Chemistry</i> , 2012 , 287, 114-122	5.4 28
1185	Angiotensin converting enzyme 2, Angiotensin-(1-7), and receptor MAS axis in the kidney. 2012 , 2012, 414128	33
1184	New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. 2012 , 2012, 147825	51
1183	Angiotensin-converting enzyme 2: the first decade. 2012 , 2012, 307315	147
1182	Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System. 2012 , 2012, 428950	36
1181	Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. 2012 , 25, 216-22	60
1180	Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. 2012 , 30, 375-83	151
1179	The renin-angiotensin system, bone marrow and progenitor cells. 2012 , 123, 205-23	54
1178	Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. 2012 , 120, 77-88	50

1177	Sexual dimorphism in rodent models of hypertension and atherosclerosis. 2012 , 167, 298-312	37
1176	Severe acute pancreatitis is associated with upregulation of the ACE2-angiotensin-(1-7)-Mas axis and promotes increased circulating angiotensin-(1-7). 2012 , 12, 451-7	17
1175	Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. 2012 , 60, 730-40	76
1174	Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. 2012 , 105, 373-85	91
1173	The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. 2012 , 27, 1835-45	58
1172	Counteraction between angiotensin II and angiotensin-(1-7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells. 2012 , 177, 12-20	36
1171	Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. 2012 , 177, 107-15	61
1170	Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure. 2012 , 9, e141-e148	3
1169	Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. 2012 , 59, 1195-203	81
1168	Carboxypeptidases A1 and A2 from the perfusate of rat mesenteric arterial bed differentially process angiotensin peptides. 2012 , 33, 67-76	11
1167	Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. 2012 , 34, 380-8	42
1166	Role of angiotensin-converting enzyme (ACE and ACE2) imbalance on tourniquet-induced remote kidney injury in a mouse hindlimb ischemia-reperfusion model. 2012 , 36, 60-70	26
1165	Angiotensin-converting enzyme 2 polymorphisms and cardiovascular risk. 2012 , 42, 1167	1
1164	An ACE for my sweet heart. 2012 , 59, 748-50	1
1163	Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. 2012 , 7, e48910	36
1162	The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond. 2012 , 10, 713-25	8
1161	Nonclassical renin-angiotensin system and renal function. 2012 , 2, 2733-52	79
1160	Altered regional blood flow distribution in Mas-deficient mice. 2012 , 6, 201-11	31

1159	Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. 2012 , 81, 520-8	86
1158	Cardiovascular Neuroendocrinology. 2012 , 307-327	2
1157	Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. 2012 , 7, e34747	62
1156	Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. 2012 , 7, e37649	42
1155	The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. 2012 , 108, 1089-96	57
1154	Novel roles of nuclear angiotensin receptors and signaling mechanisms. 2012 , 302, R518-30	104
1153	ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. 2012 , 487, 477-81	756
1152	Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. 2012 , 123, 225-39	64
1151	Angiotensin-(1-7) induces peripheral antinociception through mas receptor activation in an opioid-independent pathway. 2012 , 89, 137-44	26
1150	Role of ACE2 in diastolic and systolic heart failure. 2012 , 17, 683-91	50
1149	ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. 2012 , 39, 6581-9	58
1148	Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. 2012 , 35, 414-28	87
1147	Postnatal ontogeny of angiotensin receptors and ACE2 in male and female rats. 2012 , 9, 21-32	58
1146	Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. 2012 , 348, 104-11	41
1145	Bradykinin-potentiating peptides: beyond captopril. 2012 , 59, 516-23	98
1144	Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. 2012 , 227, 2117-22	78
1143	Local renin-angiotensin systems in the genitourinary tract. 2012 , 385, 13-26	7
1142	Peptidyl-Dipeptidase A/Angiotensin I-Converting Enzyme. 2013 , 480-494	10

1141	ACE2, angiotensin-(1 β), and Mas: the other side of the coin. 2013 , 465, 79-85	103
1140	Evolving concepts on regulation and function of renin in distal nephron. 2013 , 465, 121-32	32
1139	Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. 2013 , 52, 783-92	251
1138	Novel approaches for the identification of inhibitors of leishmanial dipeptidylcarboxypeptidase. 2013 , 8, 1127-34	2
1137	Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. 2013 , 145, 874-884.e5	76
1136	Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design. 2013 , 40, 535-41	4
1135	Osthole protects lipopolysaccharide-induced acute lung injury in mice by preventing down-regulation of angiotensin-converting enzyme 2. 2013 , 48, 819-24	39
1134	Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. 2013 , 19, 605-10	19
1133	The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. 2013 , 378, 15-22	58
1132	Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. 2013 , 18, 138-51	45
1131	ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. 2013 , 15, 866-73	135
1130	Angiotensin converting enzyme 2: a new important player in the regulation of glycemia. 2013 , 65, 731-8	33
1129	Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. 2013 , 304, C945-53	35
1128	The discovery of the ACE2 gene. 2013 , 112, 1307-9	15
1127	ACE2 alterations in kidney disease. 2013 , 28, 2687-97	84
1126	Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension. 2013 , 15, 31-8	44
1125	Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. 2013 , 216, R1-R17	349
1124	Angiotensin converting enzyme 2 and atherosclerosis. 2013 , 226, 3-8	39

1123	The ACE2 gene: its potential as a functional candidate for cardiovascular disease. 2013 , 124, 65-76	64
1122	Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. 2013 , 373, 189-94	32
1121	Angiotensin-(1-7) inhibits vascular calcification in rats. 2013 , 42, 25-34	26
1120	The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. 2013 , 219, R13-35	217
1119	Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL4 2013 , 95, 54-8	13
1118	Antinociceptive response in transgenic mice expressing rat tonin. 2013 , 713, 1-5	4
1117	Augmenting endothelial repair in diabetes: role of bone marrow-derived cells. 2013 , 37, 315-8	6
1116	Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. 2013 , 98, 109-22	52
1115	ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. 2013 , 169, 477-92	331
1114	The Renin-Angiotensin System. 2013 , 427-450	
1113	Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?. 2013 , 40, 551-9	65
1112	Sex and gender differences in cardiovascular drug therapy. 2012 , 211-36	32
1111	Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system. 2013 , 9, 23-38	14
1110	The effects of para-chloromercuribenzoic acid and different oxidative and sulfhydryl agents on a novel, non-AT1, non-AT2 angiotensin binding site identified as neurolysin. 2013 , 184, 104-14	4
1109	Changes in gene expression in the frontal cortex of rats with pilocarpine-induced status epilepticus after sleep deprivation. 2013 , 27, 378-84	11
1108	Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. 2013 , 62, 223-33	83
1107	Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats. 2013 , 106, 196-201	20
1106	Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line. 2013 , 154, 214-21	16

1105	Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. 2013 , 62, 746-52	84
1104	Angiotensin II-independent angiotensin-(1-7) formation in rat hippocampus: involvement of thimet oligopeptidase. 2013 , 62, 879-85	31
1103	Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?. 2013 , 28, 2200-2	14
1102	Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice. 2013 , 304, F1335-46	32
1101	Angiotensin-Converting Enzyme 2 Deficiency Aggravates Glucose Intolerance via Impairment of Islet Microvascular Density in Mice with High-Fat Diet. 2013 , 2013, 405284	18
1100	Angiotensin-converting enzymes play a dominant role in fertility. 2013 , 14, 21071-86	61
1099	Regulation of urinary ACE2 in diabetic mice. 2013 , 305, F600-11	52
1098	Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. 2013 , 305, R1323-30	26
1097	Dietary sodium intake modulates renal excretory responses to intrarenal angiotensin (1-7) administration in anesthetized rats. 2013 , 304, R260-6	14
1096	ACE2 gene polymorphisms and invasively measured central pulse pressure in cardiac patients indicated for coronarography. 2013 , 14, 220-6	7
1095	Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. 2013 , 112, 1104-11	250
1094	Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. 2013 , 591, 2275-85	26
1093	Silencing of angiotensin-converting enzyme by RNA interference prevents H9c2 cardiomyocytes from apoptosis induced by anoxia/reoxygenation through regulation of the intracellular renin-angiotensin system. 2013 , 32, 1380-6	6
1092	High glucose activates the alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes in pancreatic β cells. 2013 , 32, 795-804	24
1091	The association between the Angiotensin-Converting Enzyme-2 gene and blood pressure in a cohort study of adolescents. 2013 , 14, 117	32
1090	Peptide Degradation (Nepriylsin and Other Regulatory Peptidases). 2013 , 1757-1764	4
1089	Apelin is a positive regulator of ACE2 in failing hearts. 2013 , 123, 5203-11	114
1088	Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension. 2013 , 11, 41-5	49

1087	Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. 2013 , 54, 4296-306	55
1086	Renin Angiotensin System in Cognitive Function and Dementia. 2013 , 2013, 1-18	25
1085	Angiotensin-Converting Enzyme-2. 2013 , 499-504	4
1084	Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. 2013 , 12, 892-900	28
1083	Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats. 2014 , 9, e98012	51
1082	Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats. 2014 , 11, 578-86	34
1081	Angiotensin-Converting Enzyme 2, the Cellular Receptor for Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. 2014 , 147-156	
1080	Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India. 2014 , 41, 145-52	35
1079	Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine. 2014 , 85, 1225-37	72
1078	Angiotensin I converting enzyme inhibitory peptides obtained after in vitro hydrolysis of pea (<i>Pisum sativum</i> var. Bajka) globulins. 2014 , 2014, 438459	38
1077	Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. 2014 , 126, 815-27	89
1076	Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. 2014 , 127, 243-9	69
1075	Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. 2014 , 126, 507-16	107
1074	Protective axis of the renin-angiotensin system in the brain. 2014 , 127, 295-306	46
1073	From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. 2014 , 5, 227	88
1072	Cerebroprotective action of angiotensin peptides in stroke. 2014 , 126, 195-205	41
1071	Albumin inhibits the insulin-mediated ACE2 increase in cultured podocytes. 2014 , 306, F1327-34	15
1070	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. 2014 , 126, 471-82	59

1069	Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems. 2014 , 5, 16	36
1068	MAS-mediated antioxidant effects restore the functionality of angiotensin converting enzyme 2-angiotensin-(1-7)-MAS axis in diabetic rat carotid. 2014 , 2014, 640329	10
1067	ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. 2014 , 2, e00264	44
1066	Classical Renin-Angiotensin system in kidney physiology. 2014 , 4, 1201-28	281
1065	Conversion of A ₁ 3 to A ₁ 0 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme. 2014 , 92, 1178-86	31
1064	The balance between human maternal plasma angiotensin II and angiotensin 1-7 levels in early gestation pregnancy is influenced by fetal sex. 2014 , 15, 523-31	13
1063	Angiotensin-(1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis. 2014 , 15, 13-21	22
1062	Receptor MAS protects mice against hypothermia and mortality induced by endotoxemia. 2014 , 41, 331-6	27
1061	ACE for all - a molecular perspective. 2014 , 8, 195-210	20
1060	Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting angiotensin-converting enzyme 1. 2014 , 63, 453-60	25
1059	Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats. 2014 , 92, 255-65	62
1058	Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. 2014 , 11, 58-63	73
1057	Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. 2014 , 66, 167-76	211
1056	Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. 2014 , 11, 413-26	254
1055	Angiotensin-(1-7). 2014 , 63, 1138-47	157
1054	Pathogenesis of Diabetic Nephropathy: Hemodynamic Alterations/Renin Angiotensin System. 2014 , 29-38	
1053	Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. 2014 , 34, 2617-23	42
1052	Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. 2014 , 64, 1248-59	107

1051	Angiotensin 1-7 reduces mortality and rupture of intracranial aneurysms in mice. 2014 , 64, 362-8	29
1050	Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. 2014 , 63, 774-82	84
1049	Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. 2014 , 64, 157-64	70
1048	Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. 2014 , 306, F629-39	73
1047	Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. 2014 , 88, 13221-30	189
1046	Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. 2014 , 92, 847-58	28
1045	ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. 2014 , 16, 420	83
1044	Functional analysis of the receptor binding domain of SARS coronavirus S1 region and its monoclonal antibody. 2014 , 36, 387-397	1
1043	Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. 2014 , 221, 235-51	32
1042	Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats. 2014 , 16, 1689-96	24
1041	Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. 2014 , 92, 558-65	24
1040	UVB-induced gene expression in the skin of <i>Xiphophorus maculatus</i> Jp 163 B. 2014 , 163, 86-94	13
1039	New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases. 2014 , 9, e93719	13
1038	Intrarenal distributions and changes of Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 in feline and canine chronic kidney disease. 2014 , 76, 45-50	11
1037	The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: A meta-analysis involving 14,122 patients. 2015 , 16, 1240-4	31
1036	Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. 2015 , 128, 649-63	66
1035	Dietary Sodium Suppresses Digestive Efficiency via the Renin-Angiotensin System. 2015 , 5, 11123	21
1034	ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. 2015 , 66, 540-50	67

1033	Association Between Angiotensin-Converting Enzyme 2 and Coronary Artery Calcification in Patients on Maintenance Hemodialysis Therapy. 2015 , 19, 466-70	5
1032	Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation. 2015 , 43, 395-404	61
1031	Hydration and beyond: neuropeptides as mediators of hydromineral balance, anxiety and stress-responsiveness. 2015 , 9, 46	15
1030	Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. 2015 , 10, e0118758	24
1029	Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. 2015 , 36, 219-24	44
1028	Angiotensin-Converting Enzyme 2 Improves Arterial Hypoxemia in Meconium-Induced Acute Lung Injury in Piglets. 2015 , 2015, 1-7	
1027	Diabetic Nephropathy Induced by Increased Ace Gene Dosage Is Associated with High Renal Levels of Angiotensin (1-7) and Bradykinin. 2015 , 2015, 674047	15
1026	The ACE2-angiotensin-(1-7)-Mas axis protects against pancreatic cell damage in cell culture. 2015 , 44, 266-72	20
1025	Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. 2015 , 28, 1418-26	24
1024	Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure. 2015 , 16, 553-8	18
1023	Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension. 2015 , 309, R1463-73	24
1022	Novel RAAS agonists and antagonists: clinical applications and controversies. 2015 , 11, 242-52	94
1021	The intrarenal generation of angiotensin II is required for experimental hypertension. 2015 , 21, 73-81	14
1020	The normal and pathologic renal medulla: a comprehensive overview. 2015 , 211, 271-80	6
1019	Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis. 2015 , 45, 274-87	24
1018	Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. 2015 , 16, 159-64	20
1017	Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. 2015 , 75, 421-7	9
1016	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. 2015 , 30, 1176-85	66

1015	ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. 2016 , 65, 85-95	138
1014	Angiotensin-(1-7) through Mas receptor activation induces peripheral antinociception by interaction with adrenoceptors. 2015 , 69, 80-5	8
1013	Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2. 2015 , 6, 5	11
1012	Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. 2015 , 41, 1468-77	44
1011	Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells. 2015 , 308, C767-77	14
1010	ACE2 and Glycemic Control. 2015 , 219-223	
1009	Mas in the Kidney. 2015 , 207-212	1
1008	ACE2 Cell Biology, Regulation, and Physiological Functions. 2015 , 185-189	45
1007	Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2. 2015 , 93, 1003-13	34
1006	Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF- κ B pathways. 2015 , 5, 8209	74
1005	A hypothesis on the conflicting results of angiotensin converting enzyme inhibitor in the prevention of contrast-induced nephropathy. 2015 , 85, 874-7	
1004	The effect of angiotensin-converting enzyme inhibition throughout a superovulation protocol in ewes. 2015 , 103, 205-10	6
1003	Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus. 2015 , 40, 101-10	22
1002	The Renin-Angiotensin System and the Kidney:New Insights and Perspectives. 2015 , 7, 1-61	
1001	Baicalin attenuates angiotensin II-induced endothelial dysfunction. 2015 , 465, 101-7	25
1000	Dynamics of ADAM17-Mediated Shedding of ACE2 Applied to Pancreatic Islets of Male db/db Mice. 2015 , 156, 4411-25	40
999	ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. 2015 , 9, 217-37	97
998	The Renin-Angiotensin System and Bone. 2015 , 13, 125-148	9

997	Multifaceted interplay among mediators and regulators of intestinal glucose absorption: potential impacts on diabetes research and treatment. 2015 , 309, E887-99	8
996	Renin-angiotensin system within the diabetic podocyte. 2015 , 308, F1-10	39
995	Diminazene protects corpus cavernosum against hypercholesterolemia-induced injury. 2015 , 12, 289-302	12
994	Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. 2015 , 93, 343-51	117
993	A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF- β cascades with restored caveolin-1 expression. 2015 , 41, 21-31	32
992	Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. 2015 , 16, 559-69	51
991	Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. 2015 , 28, 15-21	174
990	N-domain angiotensin-I converting enzyme is expressed in immortalized mesangial, proximal tubule and collecting duct cells. 2015 , 72, 380-90	3
989	Angiotensin-converting enzyme inhibitors reduce oxidative stress intensity in hyperglycemic conditions in rats independently from bradykinin receptor inhibitors. 2016 , 57, 371-80	10
988	Angiotensin Converting Enzymes. 2016 , 263-e29D-4	1
987	Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. 2016 , 2016, 8917578	45
986	Angiotensin converting enzyme 2 and the kidney. 2016 , 25, 59-66	22
985	Risk Factors in Adolescent Hypertension. 2016 , 3, 2333794X15625159	32
984	Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures. 2016 , 138, 74-85	59
983	Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. 2016 , 67, 503-9	22
982	Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells. 2016 , 24, 1342-50	54
981	Angiotensin-converting enzyme 2. 2016 , 147, 120-1	4
980	Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF- κ B signaling pathways. 2016 , 6, 27911	106

979	Blood Pressure, Proteases and Inhibitors. 2016 , 746-752	
978	Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice. 2016 , 311, L1141-L1148	24
977	Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction. 2016 , 68, 2652-2666	24
976	Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. 2016 , 50, 229-240	22
975	The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure. 2016 , 164, 126-34	35
974	The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. 2016 , 97, 180-90	109
973	Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. 2016 , 118, 1313-26	478
972	Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. 2016 , 186, 1688-700	40
971	Cardioprotective effects of diminazene aceturate in pressure-overloaded rat hearts. 2016 , 155, 63-9	15
970	Renin-angiotensin system gene expression and neurodegenerative diseases. 2016 , 17,	18
969	Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid- β and tau pathology. 2016 , 8, 50	107
968	Angiotensin-(1-7) Selectively Induces Relaxation and Modulates Endothelium-Dependent Dilation in Mesenteric Arteries of Salt-Fed Rats. 2016 , 53, 105-118	10
967	FGF23 from bench to bedside. 2016 , 310, F1168-74	49
966	Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model. 2016 , 306, 17-26	44
965	ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. 2016 , 5, 306-11	72
964	ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. 2016 , 107, 154-162	141
963	Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?. 2016 , 310, H137-52	162
962	Pathophysiological role of osteopontin and angiotensin II in atherosclerosis. 2016 , 471, 5-9	20

961	Sex-Specific Changes in Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression and Enzyme Activity at Birth and Over the First Year of Life. 2016 , 23, 200-10	19
960	A Review of Potential Marine-derived Hypotensive and Anti-obesity Peptides. 2016 , 56, 92-112	50
959	Sex differences in stroke across the lifespan: The role of T lymphocytes. 2017 , 107, 127-137	12
958	The intrauterine renin-angiotensin system: Sex-specific effects on the prevalence of spontaneous preterm birth. 2017 , 44, 605-610	5
957	Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients. 2017 , 90, 63-68	17
956	The correlation between inflammatory injury induced by LPS and RAS in EpH4-Ev cells. 2017 , 46, 23-30	5
955	Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort. 2017 , 242, 554-563	16
954	Macrophages in neuroinflammation: role of the renin-angiotensin-system. 2017 , 469, 431-444	23
953	Use of a Fluorescent Substrate to Measure ACE2 Activity in the Mouse Abdominal Aorta. 2017 , 1614, 61-67	0
952	A Brief Introduction into the Renin-Angiotensin-Aldosterone System: New and Old Techniques. 2017 , 1614, 1-19	3
951	The effects of angiotensin-(1-7) on the exchanger NHE3 and on [Ca] in the proximal tubules of spontaneously hypertensive rats. 2017 , 313, F450-F460	5
950	Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. 2017 , 313, F487-F494	26
949	Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. 2017 , 121, 225-233	8
948	Effects of Antihypertensive Agents on Intestinal Contractility in the Spontaneously Hypertensive Rat: Angiotensin Receptor System Downregulation by Losartan. 2017 , 360, 260-266	12
947	ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury. 2017 , 26, 645-659	16
946	Kidney-brain axis inflammatory cross-talk: from bench to bedside. 2017 , 131, 1093-1105	35
945	Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA. 2017 , 7, 350-365	46
944	The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. 2017 , 125, 21-38	243

943	Regulation of the prorenin - angiotensin system by oxygen and miRNAs; parallels between placentation and tumour development?. 2017 , 56, 27-33	0
942	Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. 2017 , 91, 1336-1346	41
941	Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. 2017 , 16, 7432-7438	202
940	Effects of Taurine on ACE, ACE2 and HSP70 Expression of Hypothalamic-Pituitary-Adrenal Axis in Stress-Induced Hypertensive Rats. 2017 , 975 Pt 2, 871-886	11
939	Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. 2017 , 11, 842-852	15
938	Imbalanced plasma ACE and ACE2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session. 2017 , 39, 719-728	12
937	Renin angiotensin system deregulation as renal cancer risk factor. 2017 , 14, 5059-5068	26
936	miRNA-200c-3p is crucial in acute respiratory distress syndrome. 2017 , 3, 17021	63
935	The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke. 2017 , 31,	40
934	Therapeutic properties of Pleurotus species (oyster mushrooms) for atherosclerosis: A review. 2017 , 20, 1251-1261	14
933	Angiotensin II Type 1 Receptor Knockdown Impairs Interleukin-1 β Induced Cytokines in Human Periodontal Fibroblasts. 2017 , 88, e1-e11	8
932	Local Renin Angiotensin Aldosterone Systems and Cardiovascular Diseases. 2017 , 101, 117-127	38
931	Renin angiotensin system in liver diseases: Friend or foe?. 2017 , 23, 3396-3406	52
930	Regulation of the Renin-Angiotensin-Aldosterone System by Reactive Oxygen Species. 2017 ,	4
929	Involvement of the Renin-Angiotensin System in Atherosclerosis. 2017 ,	1
928	The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. 2017 , 8, 276	57
927	Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension. 2017 , 15, 3905-3911	33
926	Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. 2017 , 18,	155

925	Angiotensin-(1-7) Promotes Resolution of Neutrophilic Inflammation in a Model of Antigen-Induced Arthritis in Mice. 2017 , 8, 1596	29
924	[Pyr]Apelin-13 Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr]Apelin-13. 2017 , 11, 92	36
923	Protective effect of angiotensin-(1-7) against hyperglycaemia-induced injury in H9c2 cardiomyoblast cells via the PI3K Akt signaling pathway. 2018 , 41, 1283-1292	2
922	Renin Angiotensin Aldosterone System and Heart Function. 2017 , 229-248	
921	Role of the ACE2-Ang-(1-7)-Mas axis in blood pressure regulation and its potential as an antihypertensive in functional foods (Review). 2017 , 16, 4403-4412	7
920	The Brain Renin-Angiotensin System. 2017 , 417-430	
919	FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. 2018 , 27, 1323-1337.e5	58
918	Changes in Renal Peritubular Capillaries in Canine and Feline Chronic Kidney Disease. 2018 , 160, 79-83	4
917	Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide. 2018 , 67, 41-49	17
916	Effects of a novel curcumin derivative on the functions of kidney in streptozotocin-induced type 2 diabetic rats. 2018 , 26, 1257-1264	13
915	AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension. 2018 , 198, 509-520	98
914	Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition. 2018 , 25, 158-165	6
913	Four decades of ocular renin-angiotensin and kallikrein-kinin systems (1977-2017). 2018 , 166, 74-83	13
912	The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update. 2018 , 122, 9-18	13
911	Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites. 2018 , 43, 189-195	36
910	Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin. 2018 , 59, 1445-1453	5
909	Tanshinone IIA attenuates paraquat-induced acute lung injury by modulating angiotensin-converting enzyme 2/angiotensin-(1-7) in rats. 2018 , 18, 2955-2962	10
908	Renin-Angiotensin System and Cardiovascular Functions. 2018 , 38, e108-e116	67

907	ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. 2018 , 51,	27
906	Physiology and Regulation of the Renin-Angiotensin-Aldosterone System. 2018 , 1-25	7
905	The Association Between ACE2 Gene Polymorphism and the Stroke Recurrence in Chinese Population. 2018 , 27, 2770-2780	14
904	Sex differences in abdominal aortic aneurysms. 2018 , 314, H1137-H1152	19
903	Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes. 2018 , 315, F263-F274	30
902	The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). 2018 , 98, 505-553	494
901	Balance and circumstance: The renin angiotensin system in wound healing and fibrosis. 2018 , 51, 34-46	17
900	Vitamin D and the Renin-Angiotensin System. 2018 , 825-847	2
899	Angiotensin-(1-7) Promotes Resolution of Eosinophilic Inflammation in an Experimental Model of Asthma. 2018 , 9, 58	47
898	The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases. 2018 , 134, 268-279	24
897	Intratubular and intracellular renin-angiotensin system in the kidney: a unifying perspective in blood pressure control. 2018 , 132, 1383-1401	22
896	Propofol prevents human umbilical vein endothelial cell injury from Ang II-induced apoptosis by activating the ACE2-(1-7)-Mas axis and eNOS phosphorylation. 2018 , 13, e0199373	13
895	Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomy. 2018 , 224, 200-206	6
894	Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. 2018 , 92, 209-225	26
893	N1-methylnicotinamide (MNAM) as a guardian of cardiovascular system. 2018 , 233, 6386-6394	15
892	Nicotine and the renin-angiotensin system. 2018 , 315, R895-R906	156
891	Genetic deletion of the Angiotensin-(1-7) receptor Mas leads to a reduced ovulatory rate. 2018 , 107, 83-88	6
890	Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril. 2018 , 19, 1470320318789323	13

889	Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression. 2019 , 13, 17-26	16
888	Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation. 2019 , 58, 101833	46
887	Dynamic Variation of RAS on Silicotic Fibrosis Pathogenesis in Rats. 2019 , 39, 551-559	10
886	Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease. 2019 , 33, 1571-1584	17
885	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. 2019 , 71, 539-570	146
884	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. 2019 , 72, 525-535	9
883	The combination of ACE I/D and ACE2 G8790A polymorphisms reveals susceptibility to hypertension: A genetic association study in Brazilian patients. 2019 , 14, e0221248	57
882	Angiotensin 1-7 alleviates aging-associated muscle weakness and bone loss, but is not associated with accelerated aging in ACE2-knockout mice. 2019 , 133, 2005-2018	19
881	Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill. 2019 , 35, 213-227	44
880	Effect of blockade of nitric oxide in heart tissue levels of Renin Angiotensin System components in acute experimental Chagas disease. 2019 , 219, 336-342	3
879	Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. 2019 , 176, 3447-3463	73
878	Role of ADAM17 in kidney disease. 2019 , 317, F333-F342	24
877	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. 2019 , 96, 906-917	23
876	Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. 2019 , 14, e0215896	12
875	Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide. 2019 , 73, 900-909	13
874	Egg White-Derived Antihypertensive Peptide IRW (Ile-Arg-Trp) Reduces Blood Pressure in Spontaneously Hypertensive Rats via the ACE2/Ang (1-7)/Mas Receptor Axis. 2019 , 63, e1900063	37
873	Interactions between local renin angiotensin system and nitric oxide in the brain of Trypanosoma cruzi infected rats. 2019 , 194, 36-40	2
872	Mas receptor deficiency augments angiotensin II-induced atherosclerosis and aortic aneurysm ruptures in hypercholesterolemic male mice. 2019 , 70, 1658-1668.e1	15

871	Loss of angiotensin-converting enzyme-related (ACER) peptidase disrupts behavioural and metabolic responses to diet in. 2019 , 222,	4
870	An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. 2019 , 6,	109
869	The renin-angiotensin system: going beyond the classical paradigms. 2019 , 316, H958-H970	134
868	Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice. 2019 , 3, 1656-1673	23
867	Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin Pathways as Novel Upstream Targets Regulating Aldosterone. 2019 ,	1
866	Ginsenoside Rg3 Attenuates Angiotensin II-Mediated Renal Injury in Rats and Mice by Upregulating Angiotensin-Converting Enzyme 2 in the Renal Tissue. 2019 , 2019, 6741057	8
865	Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models. 2019 , 112, 78-84	14
864	BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system. 2019 , 140, 9-17	5
863	ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. 2019 , 44, 1323-1329	82
862	Proapelin is processed extracellularly in a cell line-dependent manner with clear modulation by proprotein convertases. 2019 , 51, 395-405	4
861	Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling. 2019 , 20,	25
860	Evidence for a role of angiotensin converting enzyme 2 in proteinuria of idiopathic nephrotic syndrome. 2019 , 39,	7
859	Therapeutic Delivery of Ang(1-7) via Genetically Modified Probiotic: A Dosing Study. 2020 , 75, 1299-1303	14
858	Counter-regulatory renin-angiotensin system in cardiovascular disease. 2020 , 17, 116-129	198
857	Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis and coronary heart disease. 2020 , 35, 153-161	18
856	Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. 2020 , 69, 841-851	114
855	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. 2020 , 71, 15-17	5
854	Development of Renin-Angiotensin-Aldosterone and Nitric Oxide System in the Fetus and Neonate. 2020 , 643-662	

853	Investigational new drug enabling angiotensin oral-delivery studies to attenuate pulmonary hypertension. 2020 , 233, 119750	22
852	Significance of the angiotensin I/angiotensin II/angiotensin-(1-7) axis in the pathogenesis of systemic sclerosis. 2020 , 34, 558-564	3
851	Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyl oligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. 2020 , 75, 173-182	110
850	Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase. 2020 , 225, 151893	17
849	Renin angiotensin system molecules and nitric oxide local interactions in the adrenal gland of <i>Trypanosoma cruzi</i> infected rats. 2020 , 119, 333-337	1
848	The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. 2020 , 47, 751-758	44
847	Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. 2020 , 76, 1526-1536	26
846	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. 2020 , 76, 1350-1367	36
845	Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2. 2020 , 113, 572-578	2
844	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. 2020 , 50, 1313-1324	41
843	ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. 2020 , 131, 110678	98
842	Nepriylsin expression and functions in development, ageing and disease. 2020 , 192, 111363	21
841	Identifying pathophysiological bases of disease in COVID-19. 2020 , 5, 15	4
840	Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?. 2020 , 7, 100052	11
839	ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. 2020 , 11, 5165	31
838	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. 2020 , 26, 1787-1795	10
837	The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. 2020 , 37, 779-785	8
836	Allele Frequency of Intron Variants and Its Association with Blood Pressure. 2020 , 39, 2095-2101	4

835	The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. 2020 , 375, 498-509	15
834	Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19: Should We Add a Cup of Coffee?. 2020 , 7, 581680	2
833	Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. 2020 , 319, H1059-H1068	13
832	Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!. 2021 , 179, 31-71	2
831	Hepatorenal syndrome in children: a review. 2021 , 36, 2203-2215	6
830	Covid-19, ACE2 and the kidney. 2020 , 230, e13539	14
829	Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. 2020 , 24, 422	378
828	COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. 2020 , 9,	125
827	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. 2020 , 257, 118058	9
826	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. 2020 , 257, 118075	57
825	Endocrine Significance of SARS-CoV-2's Reliance on ACE2. 2020 , 161,	72
824	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. 2020 , 8, e00623	7
823	Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity. 2020 , 11, 599729	3
822	Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. 2020 , 32, 1041-1051.e6	71
821	Cardiovascular Manifestations of COVID-19 Infection. 2020 , 9,	49
820	Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. 2020 , 3, 715	8
819	Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. 2020 , 21, 1311-1329	16
818	Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. 2020 , 12,	8

817	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. 2020 , 5, 283	399
816	ACE2 partially dictates the host range and tropism of SARS-CoV-2. 2020 , 18, 4040-4047	14
815	The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease. 2020 , 15, 2633105520975743	7
814	Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. 2020 , 21,	8
813	Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies. 2020 , 17, 3125-3145	3
812	Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity. 2020 , 68, 13982-13989	26
811	Characterization of changes in global gene expression in the hearts and kidneys of transgenic mice overexpressing human angiotensin-converting enzyme 2. 2020 , 36, 23	0
810	The concern about ACE/ARB and COVID-19: Time to hold your horses!. 2020 , 60, e88-e90	3
809	Cutaneous, skin histopathological manifestations and relationship to COVID-19 infection patients. 2020 , 33, e14157	10
808	SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. 2020 , 12,	7
807	Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. 2020 , 100, 107697	32
806	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. 2020 , 116, 2185-2196	13
805	The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. 2020 , 9,	21
804	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. 2020 , 28, 683-699	17
803	The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation. 2020 , 34, 10505-10515	25
802	Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1,880 Cases in Leishenshan Hospital, Wuhan. 2020 , 11, 478	17
801	Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. 2020 , 11, 530	43
800	Design of an engineered ACE2 as a novel therapeutics against COVID-19. 2020 , 505, 110425	8

799	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. 2020 , 1,	10
798	Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. 2020 , 8, 9-19	69
797	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. 2020 , 885, 173450	9
796	Roles of flavonoids against coronavirus infection. 2020 , 328, 109211	124
795	Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes. 2020 , 19, 4609-4623	12
794	Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients. 2020 , 319, L596-L602	5
793	Impact of COVID-19 and other viruses on reproductive health. 2020 , 52, e13791	29
792	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. 2020 , 13, 1-26	4
791	ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population. 2020 , 510, 455-458	35
790	ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle. 2020 , 11, 574753	26
789	Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome. 2020 , 21,	20
788	The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection. 2021 , 288, 5055-5070	2
787	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. 2020 , 7, 588618	49
786	SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications. 2020 , 11, 562913	5
785	Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. 2021 , 21, 13-127	16
784	Central Nervous System Manifestations Associated with COVID-19. 2020 , 20, 60	32
783	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. 2020 , 113, 797-810	1
782	Comparative ACE2 variation and primate COVID-19 risk. 2020 , 3, 641	83

781	AI (Artificial Intelligence) and Hypertension Research. 2020 , 22, 70	3
780	Prognostic and Immunological Value of Angiotensin-Converting Enzyme 2 in Pan-Cancer. 2020 , 7, 189	6
779	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. 2020 , 3, 790-800	14
778	Environmental Nanoparticles, SARS-CoV-2 Brain Involvement, and Potential Acceleration of Alzheimer's and Parkinson's Diseases in Young Urbanites Exposed to Air Pollution. 2020 , 78, 479-503	15
777	SARS-CoV-2 Infectivity and Neurological Targets in the Brain. 2020 , 1	68
776	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. 2020 , 148, 25-33	15
775	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. 2020 , 76, 1339-1349	86
774	Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. 2020 , 33, 1102-1111	27
773	Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing Risk Factor for Severe COVID-19. 2020 , 5,	3
772	Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. 2020 , 8, 559841	23
771	The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. 2020 , 15, e0239508	44
770	From ACE2 to COVID-19: A multiorgan endothelial disease. 2020 , 100, 425-430	6
769	Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. 2020 , 21,	12
768	Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. 2021 , 8, 973-980	15
767	[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. 2020 , 74, 611-614	
766	The protein expression profile of ACE2 in human tissues. 2020 , 16, e9610	405
765	[ACE2 - the hijacked all-rounder]. 2020 , 15, 1-4	0
764	Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. 2020 , 21,	49

763	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2. 2020 , 76, 651-661	38
762	Susceptibility of the Iranian population to severe acute respiratory syndrome coronavirus 2 infection based on variants of angiotensin I converting enzyme 2. 2020 , 15, 507-514	2
761	Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders. 2020 , 7, 515	3
760	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. 2020 , 6, 18	66
759	Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets. 2020 , 11, 586892	13
758	Statins in COVID-19: Is there any foundation?. 2020 , 32, 278-281	1
757	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. 2020 , 85, 104510	6
756	Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. 2020 , 7, 594495	63
755	How Does SARS-CoV-2 Affect the Central Nervous System? A Working Hypothesis. 2020 , 11, 582345	15
754	The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. 2020 , 21,	10
753	Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways. 2020 , 2020, 8896536	5
752	Osmotic Adaptation by Na-Dependent Transporters and ACE2: Correlation with Hemostatic Crisis in COVID-19. 2020 , 8,	6
751	Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. 2020 , 7,	22
750	Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19. 2020 , 7, 588692	5
749	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11
748	ACE2: The Major Cell Entry Receptor for SARS-CoV-2. 2020 , 198, 867-877	88
747	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. 2020 , 177, 4942-4966	51
746	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. 2020 , 19, 102569	121

745	Potential influence of COVID-19/ACE2 on the female reproductive system. 2020 , 26, 367-373	146
744	Is there an impact of the COVID-19 pandemic on male fertility? The ACE2 connection. 2020 , 318, E878-E880	33
743	An Overview of the Potential Use of Ethno-Medicinal Plants Targeting the Renin-Angiotensin System in the Treatment of Hypertension. 2020 , 25,	3
742	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. 2020 , 21,	183
741	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. 2020 , 15, 759-766	66
740	Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?. 2020 , 26, 11	12
739	ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. 2020 , 53, 425-435	264
738	JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. 2020 , 181, 467-475	102
737	Advances in the relationship between coronavirus infection and cardiovascular diseases. 2020 , 127, 110230	38
736	Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. 2020 , 53, 43-52	58
735	Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. 2020 , 130, 106680	31
734	Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice. 2020 , 100, 1169-1183	14
733	Chemical renal denervation-induced upregulation of the ACE2/Ang (1-7)/Mas axis attenuates blood pressure elevation in spontaneously hypertensive rats. 2020 , 42, 661-668	6
732	COVID-19: ACE2centric Infective Disease?. 2020 , 76, 294-299	39
731	The immune system and COVID-19: Friend or foe?. 2020 , 256, 117900	142
730	Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. 2020 , 47, 4383-4392	87
729	Is the kidney a target of SARS-CoV-2?. 2020 , 318, F1454-F1462	105
728	Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats. 2020 , 42, 1307-1321	11

727	Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. 2020 , 6, 98-105	25
726	Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients. 2020 , 28, 721-725	138
725	Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. 2020 , 73, 366-369	83
724	Diabetes and metabolic syndrome as risk factors for COVID-19. 2020 , 14, 671-677	43
723	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. 2020 , 109, 1446-1459	34
722	Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. 2020 , 148, e106	49
721	ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. 2020 , 222, 556-563	194
720	ACE2 and COVID-19 and the resulting ARDS. 2020 , 96, 403-407	63
719	Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. 2020 , 144, 109988	12
718	Apelin-potential therapy for COVID-19?. 2020 , 145, 84-87	10
717	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. 2020 , 14, 7760-7782	172
716	Cerebrovascular and Neurological Dysfunction under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping?. 2020 , 21,	17
715	A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. 2020 , 177, 4866-4872	25
714	What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?. 2020 , 143, 109886	14
713	COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. 2020 , 32, 1599-1608	138
712	A new normal for hypertension medicine with coronavirus disease-2019 (COVID-19): proposal from the president of the Japanese Society of Hypertension. 2020 , 43, 857-858	5
711	Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience. 2020 , 11, 659	27
710	The ACE2/Ang (1-7)/MasR axis as an emerging target for antihypertensive peptides. 2021 , 61, 2572-2586	9

709	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. 2020 , 6, 315-331	716
708	Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. 2020 , 75, 1382-1385	323
707	Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. 2020 , 21,	15
706	Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. 2020 , 92, 726-730	271
705	Diabetes is a risk factor for the progression and prognosis of COVID-19. 2020 , 36, e3319	721
704	Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. 2020 , 17, 313	62
703	Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil. 2020 , 5, 8312-8320	127
702	Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection. 2020 , 30, e2122	24
701	ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19. 2020 ,	23
700	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. 2020 , 10, 7448-7464	102
699	Revealing the synergistic mechanism of Shenfu Decoction for anti-heart failure through network pharmacology strategy. 2020 , 18, 536-549	1
698	Angiotensin-II and angiotensin-(1-7) imbalance affects comorbidity of depression and coronary heart disease. 2020 , 131, 170353	3
697	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. 2020 , 9,	46
696	The Impact of COVID-19 on Cancer Risk and Treatment. 2020 , 13, 1-7	18
695	Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. 2020 , 46, 835-837	34
694	ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. 2020 , 9,	19
693	Folic acid and RAAS blockers in ischemia/reperfusion-induced hepatic injury: A current mechanistic concept for understanding the incidence, significance & outcome. 2020 , 327, 109187	0
692	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. 2020 , 14, 601-612	28

691	SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction. 2020 , 21,	48
690	Statins in COVID-19: is there any foundation?. 2020 , 32, 278-281	11
689	Considerations for people with diabetes during the Coronavirus Disease (COVID-19) pandemic. 2020 , 166, 108296	11
688	The renin angiotensin aldosterone system and COVID-19. 2020 , 28, 977-984	4
687	Acute Kidney Injury in a Case Series of Patients with Confirmed COVID-19 (Coronavirus Disease 2019): Role of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Blockade. 2020 , 2020, 8811931	4
686	Molecular Aspects of COVID-19 Differential Pathogenesis. 2020 , 9,	11
685	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. 2020 , 16, 2382-2391	41
684	Antiviral anticoagulation. 2020 , 4, 774-788	9
683	Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury. 2020 , 35, 256-258	61
682	Mesenchymal stem cells modified with angiotensin-converting enzyme 2 are superior for amelioration of glomerular fibrosis in diabetic nephropathy. 2020 , 162, 108093	12
681	B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. 2020 , 11, 1058	32
680	Role of brain renin angiotensin system in neurodegeneration: An update. 2020 , 27, 905-912	50
679	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. 2020 , 27, 484-511	10
678	ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?. 2020 , 12,	84
677	An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations. 2020 , 141, 108-109	3
676	Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. 2020 , 43, 588-590	52
675	The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. 2020 , 116, 1932-1936	41
674	Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review. 2020 , 52, 191-206	13

673	Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. 2020 , 81, e16-e25	1085
672	Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. 2020 , 41,	235
671	Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. 2020 , 75, 3085-3095	90
670	Renin-angiotensin-aldosterone system and COVID-19 infection. 2020 , 81, 63-67	45
669	Renin-angiotensin system at the heart of COVID-19 pandemic. 2020 , 174, 30-33	88
668	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. 2020 , 47, 107228	77
667	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. 2020 , 76, 14-20	652
666	Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. 2020 , 112, 102463	160
665	Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. 2020 , 30, 1061-1067	52
664	[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. 2020 , 145, 682-686	4
663	Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. 2020 , 116, 1688-1699	200
662	Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. 2020 , 318, H1080-H1083	28
661	Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. 2020 , 126, 1456-1474	1012
660	Targeting Angiotensin-Converting Enzyme-2/Angiotensin-(1-7)/Mas Receptor Axis in the Vascular Progenitor Cells for Cardiovascular Diseases. 2021 , 99, 29-38	14
659	Renin-angiotensin system molecules are associated with subclinical atherosclerosis and disease activity in rheumatoid arthritis. 2021 , 31, 119-126	10
658	An update on ACE2 amplification and its therapeutic potential. 2021 , 231, e13513	12
657	Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. 2021 , 62, 13-23	19
656	Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. 2021 , 31, 410-424	62

655	Protective effects of <i>Saraca indica</i> L. leaves extract (family Fabaceae) against gamma irradiation induced injury in the kidney of female albino rats. 2021 , 36, 506-519	0
654	Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease. 2021 , 35, 33-42	3
653	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?. 2021 , 17, 275-284	3
652	Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2). 2021 , 74, 285-290	17
651	Advances in research on ACE2 as a receptor for 2019-nCoV. 2021 , 78, 531-544	50
650	An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. 2021 , 17, 92-97	3
649	2020 update on the renin-angiotensin-aldosterone system in pediatric kidney disease and its interactions with coronavirus. 2021 , 36, 1407-1426	13
648	Children were less frequently infected with SARS-CoV-2 than adults during 2020 COVID-19 pandemic in Warsaw, Poland. 2021 , 40, 541-547	7
647	The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI). 2021 , 218, 107684	7
646	Overexpression of the SARS-CoV-2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia. 2021 , 253, 17-30	23
645	Air pollution by NO and PM explains COVID-19 infection severity by overexpression of angiotensin-converting enzyme 2 in respiratory cells: a review. 2020 , 19, 1-18	64
644	Renin-angiotensin system at the interface of COVID-19 infection. 2021 , 890, 173656	12
643	SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: a review. 2021 , 40, 188-192	11
642	Drug screening and development from the affinity of S protein of new coronavirus with ACE2. 2021 , 40, 715-723	2
641	The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. 2021 , 135, 170428	5
640	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. 2021 , 11, 1-12	40
639	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. 2021 , 221, 107750	16
638	ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. 2021 , 150, 104621	30

637	Neurological manifestations of coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19. 2021 , 1-8	8
636	Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis. 2021 , 93, 2287-2300	13
635	Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications. 2021 , 76, 109-124	21
634	Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2. 2021 , 890, 173642	4
633	Relevance of angiotensin-(1-7) and its receptor Mas in pneumonia caused by influenza virus and post-influenza pneumococcal infection. 2021 , 163, 105292	3
632	Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. 2021 , 31, 745-755	24
631	The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. 2021 , 538, 80-87	10
630	Micronutrients and bioactive substances: Their potential roles in combating COVID-19. 2021 , 84, 111103	16
629	The cardiovascular aspect of COVID-19. 2021 , 53, 227-236	16
628	Journey to a Receptor for Advanced Glycation End Products Connection in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: With Stops Along the Way in the Lung, Heart, Blood Vessels, and Adipose Tissue. 2021 , 41, 614-627	10
627	The implications of COVID-19 infection on the endothelium: A metabolic vascular perspective. 2021 , 37, e3402	9
626	Glycyrrhizin: An old weapon against a novel coronavirus. 2021 , 35, 629-636	24
625	Coronavirus: A possible cause of reduced male fertility. 2021 , 9, 80-87	12
624	ACE2: Its potential role and regulation in severe acute respiratory syndrome and COVID-19. 2021 , 236, 2430-2442	18
623	COVID-19 and diabetes; Possible role of polymorphism and rise of telemedicine. 2021 , 15, 4-9	7
622	The ACE2 as a rescue protein or suspect enzyme in COVID-19: possible application of the Engineered inactive hrsACE2 as a safer therapeutic agent in the treatment of SARS-CoV-2 infection. 2021 , 18, 495-502	4
621	Alpha-1-antitrypsin: A possible host protective factor against Covid-19. 2021 , 31, e2157	27
620	Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. 2021 , 26, 371-380	11

619	Physical activity and nutrition guidelines to help with the fight against COVID-19. 2021 , 39, 101-107	35
618	Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. 2021 , 99, 192-205	1
617	The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. 2021 , 26, 961-971	2
616	Lactic dehydrogenase-lymphocyte ratio for predicting prognosis of severe COVID-19. 2021 , 100, e24441	3
615	Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach. 2021 , 24, 100597	13
614	The Fatty Acid Lipid Metabolism Nexus in COVID-19. 2021 , 13,	25
613	COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. 2021 , 1	5
612	A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. 2021 , 53, 205-214	64
611	ACE2 in the second act of COVID-19 syndrome: Peptide dysregulation and possible correction with oestrogen. 2021 , 33, e12935	7
610	The coronavirus disease 2019 and effect on liver function. 2021 , Publish Ahead of Print,	6
609	SARS-CoV-2 and the reproductive system: known and the unknown...!. 2021 , 26, 1	14
608	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. 2021 , 3, 192-197	0
607	SARS-CoV-2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. 2021 , 58, 2465-2480	21
606	Exploring G protein-coupled receptors and yeast surface display strategies for viral detection in baker's yeast: SARS-CoV-2 as a case study. 2021 , 21,	2
605	ACE2 gene transfer ameliorates vasoreparative dysfunction in CD34+ cells derived from diabetic older adults. 2021 , 135, 367-385	2
604	A Potential Role of the Renin-Angiotensin-System for Disturbances of Respiratory Chemosensitivity in Acute Respiratory Distress Syndrome and Severe Acute Respiratory Syndrome. 2020 , 11, 588248	2
603	The Dynamic Expression of Potential Mediators of Severe Acute Respiratory Syndrome Coronavirus 2 Cellular Entry in Fetal, Neonatal, and Adult Rhesus Monkeys. 2020 , 11, 607479	2
602	Angiotensin converting enzyme. 2021 , 505-508	1

601	Coronavirus: Pure Infectious Disease or Genetic Predisposition. 2021 , 1318, 91-107	1
600	Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles. 2021 , 40, 100356	5
599	High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. 2021 , 27, 100321	3
598	COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. 2021 ,	1
597	Sex Differences and COVID-19. 2021 , 1327, 79-91	2
596	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. 2021 , 40, 905-919	109
595	ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues. 2021 , 15, 8	16
594	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. 2021 , 28, 9	52
593	Targeting the Protective Arm of the Renin-Angiotensin System: Focused on Angiotensin-(1-7). 2021 , 377, 64-74	3
592	The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. 2021 , 48, 1763-1771	2
591	The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients. 2021 , 22, 1470320320987118	4
590	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. 2020 , 11, 599736	3
589	The role of SARS-CoV-2 target ACE2 in cardiovascular diseases. 2021 , 25, 1342-1349	7
588	Therapy with RAS inhibitors during the COVID-19 pandemic. 2021 , 22, 329-334	4
587	Effects of Angiotensin II Type 1A Receptor on ACE2, Nephilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension. 2020 , 11, 602985	4
586	Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field. 1	4
585	Association between angiotensin converting enzyme gene polymorphism and essential hypertension: A systematic review and meta-analysis. 2021 , 22, 1470320321995074	3
584	ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. 2021 , 135, 387-407	13

583	Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. 2021 , 135, 1-17	11
582	A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. 2021 ,	38
581	Human eggs, zygotes, and embryos express the receptor angiotensin 1-converting enzyme 2 and transmembrane serine protease 2 protein necessary for severe acute respiratory syndrome coronavirus 2 infection. 2021 , 2, 33-42	8
580	Renin-angiotensin system: A possible clue for gender bias in coronavirus disease 2019 infection. 2, 7-11	
579	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. 2020 , 7, 629933	15
578	Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities. 2021 , 34, 187-198	1
577	Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options. 2021 , 10,	5
576	Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. 2021 , 12, 624052	8
575	Peripheral Nervous System Manifestations Associated with COVID-19. 2021 , 21, 9	38
574	NO, ROS, RAS, and PVAT: More Than a Soup of Letters. 2021 , 12, 640021	4
573	Expression of ACE2 receptor, soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin (1-7), is modulated in COVID-19 patients.	1
572	Ginsenoside Rc Ameliorates Endothelial Insulin Resistance via Upregulation of Angiotensin-Converting Enzyme 2. 2021 , 12, 620524	2
571	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. 2021 , 22, 254-281	17
570	A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. 2021 , 35, e21419	3
569	ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders. 2021 , 135, 535-554	8
568	SARS-CoV-2 Infection-Induced Promoter Hypomethylation as an Epigenetic Modulator of Heat Shock Protein A1L (HSPA1L) Gene. 2021 , 12, 622271	11
567	The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. 2021 , 16, e0246190	33
566	Determining available strategies for prevention and therapy: Exploring COVID-19 from the perspective of ACE2 (Review). 2021 , 47,	3

565	Structural analysis of COVID-19 spike protein in recognizing the ACE2 receptor of different mammalian species and its susceptibility to viral infection. 2021 , 11, 109	13
564	Angiotensin-Converting Enzyme Type 2 as a Molecular Mediator for Infection of Cells with SARS-CoV and SARS-CoV-2 Viruses. 2021 , 51, 381-389	1
563	Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease. 2021 , 25, 3840-3855	9
562	Metabolism of angiotensin peptides by angiotensin converting enzyme 2 (ACE2) and analysis of the effect of excess zinc on ACE2 enzymatic activity. 2021 , 137, 170477	2
561	The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies. 2021 ,	
560	Effects of Pennyroyal (<i>Mentha pulegium</i> L.) on Angiotensin Converting Enzyme-2 (ACE-2) and Antioxidant Parameters in Rabbits.	0
559	Angiotensin (1-7) Expressing Probiotic as a Potential Treatment for Dementia.. 2021 , 2,	0
558	Cytoplasmic domain and enzymatic activity of ACE2 is not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells.	
557	Epigenetic Lens to Visualize the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection in COVID-19 Pandemic. 2021 , 12, 581726	14
556	Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. 2021 , 12, 619524	9
555	COVID-19 pandemic: what about the gonads?. 2021 , 20, 259-268	5
554	Renal Manifestations of Covid-19: Physiology and Pathophysiology. 2021 , 10,	9
553	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.	
552	An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2. 2021 , 125, 2533-2550	7
551	The Impact of Frailty on COVID-19 Outcomes: A Systematic Review and Meta-analysis of 16 Cohort Studies. 2021 , 25, 702-709	8
550	The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. 2021 , 23, 17	1
549	Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019. 2021 , 36, 247-262	1
548	Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2. 2021 , 2, 025024	7

547	ACE2 protein expression within isogenic cell lines is heterogeneous and associated with distinct transcriptomes. 2021,	1
546	Dual role for angiotensin-converting enzyme 2 in Severe Acute Respiratory Syndrome Coronavirus 2 infection and cardiac fat. 2021, 22, e13225	3
545	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. 2021, 9,	7
544	The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms. 2021, 1-20	2
543	Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19. 2021, 41, 129-138	39
542	Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. 2021, 8, 620990	5
541	Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease. 2021, 320, L422-L429	14
540	Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. 2021, 27, 1531-1552	4
539	The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling. 2021, 22,	7
538	Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis. 2021, 9, e1672	8
537	Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. 2021, 82, 1124-1130	18
536	COVID-19 and Cancer: Biological Interconnection and Treatment.	
535	Hypertension, a Moving Target in COVID-19: Current Views and Perspectives. 2021, 128, 1062-1079	22
534	Drugs acting on the renin-angiotensin system and SARS-CoV-2. 2021, 26, 870-874	22
533	Aging versus youth: Endocrine aspects of vulnerability for COVID-19. 2021, 1	3
532	Potency of SARS-CoV-2 on Ocular Tissues.	
531	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. 2021, 136, 111193	14
530	The fight against COVID-19: Striking a balance in the renin-angiotensin system. 2021, 26, 2214-2220	7

529	Neurotropic Viruses, Astrocytes, and COVID-19. 2021 , 15, 662578	19
528	Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. 2021 , 35, 109020	22
527	Angiotensin-(3-4) modulates the overweight- and undernutrition-induced ACE2 downregulation in renal proximal tubule cells: implications for COVID-19?.	0
526	The homology analysis of ACE2 gene and its distinct expression in laboratory and wild animals.	
525	[Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19]. 2021 , 16, 1-3	0
524	Dysregulation of the Renin-Angiotensin-Aldosterone System (RAA) in Patients Infected with SARS-CoV-2-Possible Clinical Consequences. 2021 , 22,	7
523	Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study. 2021 , 896, 173899	11
522	RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection. 2021 , 193, 1744-1756	2
521	Nano-size dependence in the adsorption by the SARS-CoV-2 spike protein over gold colloid. 2021 , 615, 126275	5
520	Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. 2021 , 14, 621-629	13
519	ACE2-based decoy receptors for SARS coronavirus 2. 2021 , 89, 1065-1078	4
518	Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2. 2021 , 93, 5487-5504	4
517	Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. 2021 , 7, 37	3
516	Molecular phyloecology suggests a trophic shift concurrent with the evolution of the first birds. 2021 , 4, 547	2
515	The understanding of the immunopathology in COVID-19 infection. 2021 , 81, 255-263	1
514	Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs. 2021 , 1-8	0
513	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. 2021 , 44, 499-513	4
512	Anti-SARS-CoV-2 Natural Products as Potentially Therapeutic Agents. 2021 , 12, 590509	9

511	Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. 2021 , 166, 2089-2108	13
510	The Use of Antihypertensive Drugs as Adjuvant Therapy in Cancer. 2021 , 11, 660943	6
509	Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients. 2021 , 10, 86-96	1
508	A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment. 2021 , 137, 111404	3
507	ACE2 expression in rat brain: implications for COVID-19 associated neurological manifestations.	2
506	The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19. 2021 , 12, 653985	1
505	SARS CoV2 infection _The longevity study perspectives. 2021 , 67, 101299	11
504	Puerarin exhibits antiinflammatory properties in gunpowder smog-induced acute lung injury in rats via regulation of the renin-angiotensin system and the NFB signaling pathway. 2021 , 22, 809	1
503	Analysis of the role of N-linked glycosylation in cell-surface expression, function and binding properties of SARS-CoV-2 receptor ACE2.	
502	Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. 2021 , 137, 111363	18
501	SARS-CoV-2 journey to the brain with a focus on potential role of docosahexaenoic acid bioactive lipid mediators. 2021 , 184, 95-103	1
500	A review on SARS-CoV-2 and stroke pathogenesis and outcome. 2021 , 57, 63	6
499	Role of the Renin-Angiotensin-Aldosterone System in Various Disease Processes: An Overview.	4
498	Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells. 2021 , 22,	2
497	Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. 2021 , 93, 5729-5741	12
496	The Significance of Angiotensin-Converting Enzyme-2 (ACE2) in SARSCov- 2 Infection and COVID-19. 2021 , 2,	
495	Variants in ACE2; potential influences on virus infection and COVID-19 severity. 2021 , 90, 104773	28
494	Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19. 2021 , 16, 1755-1765	15

493	Plasma ACE2 species are differentially altered in COVID-19 patients. 2021 , 35, e21745	7
492	The key role of the level of ACE2 gene expression in SARS-CoV-2 infection. 2021 , 13, 14552-14556	5
491	Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. 2021 , 73, 1539-1550	4
490	The structural reformation of peptides in enhancing functional and therapeutic properties: Insights into their solid state crystallizations. 2021 , 273, 106565	1
489	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. 2021 , 3, 1257-1272	3
488	Does Hypofractionated Radiotherapy Regimens Increase the Vulnerability to SARS- COV-2 by Influencing ACE-2 Activity?. 2021 , 2, 419-421	
487	Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. 2021 , 126, 1-46	3
486	Angiotensin-(1-7) and Mas receptor in the brain. 2021 , 2, 268-293	2
485	Do Changes in Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms. 2021 , 22,	6
484	Emerging importance of ACE2 in external stratified epithelial tissues. 2021 , 529, 111260	0
483	Angiotensin-converting enzyme 2: a key enzyme in key organs. 2022 , 23, 1-11	1
482	Regulated Intramembrane Proteolysis of ACE2: A Potential Mechanism Contributing to COVID-19 Pathogenesis?. 2021 , 12, 612807	7
481	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. 2021 , 6, 233	60
480	The Role of Renin: Angiotensin: Aldosterone System in the Pathogenesis and Pathophysiology of COVID-19.	
479	Advances in use of mouse models to study the renin-angiotensin system. 2021 , 529, 111255	2
478	Angiotensin receptors in the kidney and vasculature in hypertension and kidney disease. 2021 , 529, 111259	2
477	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. 2021 , 344, 77-110	3
476	Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients. 2021 , 12, 625732	22

475	Coronary microvascular dysfunction pathophysiology in COVID-19. 2021 , 28, e12718	10
474	Role of ACE 2 and Vitamin D: The Two Players in Global Fight against COVID-19 Pandemic.	
473	New perspectives on angiotensin-converting enzyme 2 and its related diseases. 2021 , 12, 839-854	1
472	Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19. 2021 , 39, 713-726	7
471	A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. 2021 , 58, 4535-4563	5
470	A possible role for ST2 as prognostic biomarker for COVID-19. 2021 , 138, 106857	8
469	Angiotensin-Converting Enzyme 2 (ACE2) as a Potential Diagnostic and Prognostic Biomarker for Chronic Inflammatory Lung Diseases. 2021 , 12,	2
468	Extracellular Matrix Remodeling in Chronic Liver Disease. 2021 , 2, 1-12	5
467	Food-Derived Bioactive Peptides: A Promising Substitute to Chemosynthetic Drugs Against the Dysregulated Renin-Angiotensin System in COVID-19 Patients. 2021 , 11, 325-355	1
466	A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. 2021 , 152, 110619	0
465	Glycosylation of SARS-CoV-2: structural and functional insights. 2021 , 413, 7179-7193	11
464	SARS-CoV-2 and pathological matrix remodeling mediators. 2021 , 70, 847-858	3
463	Alterations in Gene Expression of Renin-Angiotensin System Components and Related Proteins in Colorectal Cancer. 2021 , 2021, 9987115	2
462	Ancient Adaptative Evolution of ACE2 in East Asians. 2021 , 13,	0
461	Development of flexible electrochemical impedance spectroscopy-based biosensing platform for rapid screening of SARS-CoV-2 inhibitors. 2021 , 183, 113213	12
460	Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies. 2021 , 33, e2101707	7
459	Editorial: The Role of the Renin-Angiotensin System in the Central Nervous System. 2021 , 15, 733084	1
458	Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?. 2021 , 1	6

457	ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients. 2021 , 191, 1154-1164	9
456	Potential drug leads for SARS-CoV2 from phytochemicals of : a Machine Learning approach. 2021 , 32, 1-9	0
455	RAAS, ACE2 and COVID-19; a mechanistic review. 2021 , 28, 6465-6470	2
454	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. 2021 , 93, 5908-5916	17
453	Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection. 2021 , 22,	6
452	The signal pathways and treatment of cytokine storm in COVID-19. 2021 , 6, 255	84
451	Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients. 2021 , 12, 700220	2
450	Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection. 2021 , 10, 2431-2446	2
449	ACE2 protein expression within isogenic cell lines is heterogeneous and associated with distinct transcriptomes. 2021 , 11, 15900	3
448	Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?. 2021 , 1-10	2
447	SARS-CoV-2 susceptibility and ACE2 gene variations within diverse ethnic backgrounds.	1
446	Ovulatory upregulation of angiotensin-converting enzyme 2, a receptor for SARS-CoV-2, in dominant follicles of the human ovary. 2021 , 116, 1631-1640	1
445	COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies. 2021 , 140, 111685	3
444	How SARS-CoV-2 might affect potassium balance via impairing epithelial sodium channels?. 2021 , 48, 6655-6661	3
443	Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility. 2021 , 135, 1805-1824	5
442	JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules. 2021 , 24, 102928	2
441	Myocardial fibrosis reversion via rhACE2-electrospun fibrous patch for ventricular remodeling prevention. 2021 , 6, 44	3
440	Covid-19 pandemic: Perspectives on management. 2021 , 146, 103344	2

439	The interaction of the severe acute respiratory syndrome coronavirus 2 spike protein with drug-inhibited angiotensin converting enzyme 2 studied by molecular dynamics simulation. 2021 , 39, 1705-1716	2
438	An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models. 2021 , 434, 167213	0
437	SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients. 2021 , 13,	3
436	A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus. 2021 , 11, 707194	4
435	The relationship of serum testosterone levels with the clinical course and prognosis of COVID-19 disease in male patients: A prospective study. 2021 ,	12
434	The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data. 2021 , 7, e07665	2
433	COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. 2021 , 9, 6178-6200	3
432	Expression pattern and function of SARS-CoV-2 Receptor ACE2. 2021 , 3, 312-312	1
431	Updates on renin-angiotensin system blockers in hypertensive patients with COVID-19. 2021 ,	1
430	Detecting SARS-CoV-2 Orf3a and E ion channel activity in COVID-19 blood samples. 2021 , 5, e196	3
429	SARS-CoV-2 Spike Protein Regulation of Angiotensin Converting Enzyme 2 and Tissue Renin-Angiotensin Systems: Influence of Biologic Sex. 2021 ,	0
428	An analysis of chronic kidney disease as a prognostic factor in pediatric cases of COVID-19. 2021 , 43, 400-409	
427	Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2. 2021 , 9, e0119921	1
426	Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. 2021 , 46, 101807	1
425	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). 2021 ,	16
424	Sex Differences in Adverse Reactions to an Inactivated SARS-CoV-2 Vaccine Among Medical Staff in China. 2021 , 8, 731593	3
423	Impact of air pollution and smoking on COVID-19: a review. 2021 , 15,	
422	SARS-CoV-2 Initiates Programmed Cell Death in Platelets. 2021 , 129, 631-646	44

421	Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19. 2021 , 40, 799-841	6
420	ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology. 2021 , 8, 708336	3
419	Post-Mortem RT-PCR Assay for SARS-CoV-2 RNA in COVID-19 Patients' Corneal Epithelium, Conjunctival and Nasopharyngeal Swabs. 2021 , 10,	3
418	Novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection: Microbiologic perspectives and anatomic considerations for sanctuary sites. 2021 , 14, 1237-1246	
417	Coronavirus disease 2019 and the gut-lung axis. 2021 , 113, 300-307	3
416	Human genetic basis of coronavirus disease 2019. 2021 , 6, 344	4
415	Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population. 2021 , 78, 1138-1149	1
414	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. 2021 , 24, 103144	9
413	Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness. 2021 , 551, 111353	0
412	ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations. 2021 , 345, 113837	14
411	Evaluation of chloroquine and hydroxychloroquine as ACE-2 Inhibitors By In Silico Approaches: Cardiac Arrhythmia Cause?. 2021 , 1244, 130946	2
410	The physiologic and pathologic roles of perivascular adipose tissue and its interactions with blood vessels and the renin-angiotensin system. 2021 , 173, 105890	6
409	COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women. 2021 ,	7
408	Computational insights into the membrane fusion mechanism of SARS-CoV-2 at the cellular level. 2021 , 19, 5019-5028	0
407	Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study. 2021 , 1	7
406	Risk Factors in Patients with Diabetes Hospitalized for COVID-19: Findings from a Multicenter Retrospective Study. 2021 , 2021, 3170190	2
405	Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile. 2021 , 40, 477-484	39
404	The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease. 2021 , 81, 160-165	5

403	The ancient cardioprotective mechanisms of ACE2 bestow SARS-CoV-2 with a wide host range.	
402	Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. 2021 , 1	4
401	Interferon-regulated genetic programs and JAK/STAT pathway activate the intronic promoter of the short ACE2 isoform in renal proximal tubules. 2021 ,	0
400	Lung adenocarcinoma patients have higher risk of SARS-CoV-2 infection. 2021 , 13, 1620-1632	7
399	Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS). 2020 , 7, 624093	5
398	Does SARS-CoV-2 Threaten Male Fertility?. 2021 , 1321, 139-146	2
397	An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19. 2021 , 236, 49-54	22
396	Angiotensin Converting Enzyme 2: A Critical Regulator of the Renin-Angiotensin System. 2006 , 129-142	1
395	Insights from the association of SARS-CoV S-protein with its receptor, ACE2. 2006 , 581, 209-18	16
394	Quenched fluorescent peptide substrates as tools for the discovery of novel cardiovascular disease biomarkers. 2009 , 611, 419-22	1
393	Renin-Angiotensin System Proteases and the Cardiometabolic Syndrome: Pathophysiological, Clinical and Therapeutic Implications. 2007 , 87-111	2
392	Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. 2014 , 259-289	4
391	Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2). 2017 , 1527, 101-115	19
390	Determining the Enzymatic Activity of Angiotensin-Converting Enzyme 2 (ACE2) in Brain Tissue and Cerebrospinal Fluid Using a Quenched Fluorescent Substrate. 2017 , 1527, 117-126	7
389	The Intrarenal Renin-Angiotensin System. 2007 , 3-22	4
388	Hypertension. 2007 , 1833-1870	3
387	Brain. 2019 , 55-71	1
386	Heart [Coronary Vessels and Cardiomyocytes. 2019 , 73-81	2

385	Kidney. 2019 , 117-130	2
384	Effects of Taurine on Blood Index of Hypothalamic Pituitary Adrenal (HPA) Axis of Stress-Induced Hypertensive Rat. 2015 , 803, 613-21	5
383	The Renin Angiotensin System and Diabetes. 2017 , 275-291	3
382	SARS Coronavirus Pathogenesis and Therapeutic Treatment Design. 2010 , 195-230	0
381	Knockout Models of the Renin-Angiotensin System. 2004 , 207-227	1
380	Role of the Renin-Angiotensin System in ARDS. 2012 , 171-181	1
379	Peptidyl-dipeptidase A/angiotensin I-converting enzyme. 2004 , 332-346	45
378	Angiotensinogen and Angiotensins. 2019 , 483-489	1
377	Therapeutic Potential of Systemic Gene Transfer Strategy for Hypertension and Cardiovascular Disease. 2007 , 429-445	15
376	The Renin-Angiotensin System. 2008 , 343-357	2
375	Vitamin D and the Renin-Angiotensin System. 2005 , 871-881	3
374	Renal Renin-Angiotensin System. 2006 , 1235-1242	6
373	The Renal Circulations and Glomerular Ultrafiltration. 2012 , 94-137	11
372	Vasoactive Molecules and the Kidney. 2012 , 384-420	2
371	SARS-CoV-2 and diabetes: New challenges for the disease. 2020 , 164, 108228	39
370	Drugs acting on renin angiotensin system and use in ill patients with COVID-19. 2020 , 75, 319-325	4
369	A historical perspective on ACE2 in the COVID-19 era. 2021 , 35, 935-939	15
368	Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?. 2020 , 43, 854-856	53

367	Identification and characterization of adipose surface epitopes. 2020 , 477, 2509-2541	6
366	ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. 2020 , 134, 747-750	41
365	Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs. 2020 , 134, 1143-1150	18
364	Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19. 2020 , 134, 2489-2501	10
363	ACE2 in the renin-angiotensin system. 2020 , 134, 3063-3078	7
362	Brain angiotensin converting enzyme-2 in central cardiovascular regulation. 2020 , 134, 2535-2547	8
361	ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. 2020 , 134, 2791-2805	7
360	ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19. 2020 , 134, 3047-3062	15
359	ACE2 as therapeutic agent. 2020 , 134, 2581-2595	4
358	Angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) and Mas receptor in gonadal and reproductive functions. 2020 , 134, 2929-2941	5
357	ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. 2020 , 134, 2851-2871	19
356	Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease. 2020 , 134, 2645-2664	6
355	ACE2: from protection of liver disease to propagation of COVID-19. 2020 , 134, 3137-3158	15
354	ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19. 2020 , 134, 3229-3232	4
353	Effects of exercise training on renal interstitial fibrosis and renin-angiotensin system in rats with chronic renal failure. 2021 , 39, 143-152	4
352	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis.	11
351	TWIRLS, an automated topic-wise inference method based on massive literature, suggests a possible mechanism via ACE2 for the pathological changes in the human host after coronavirus infection.	1
350	TWIRLS, an automated topic-wise inference method based on massive literature, suggests a possible mechanism via ACE2 for the pathological changes in the human host after coronavirus infection.	5

349	Establishing Prokaryotic Expression System of Angiotensin-Converting Enzyme 2 (ACE2) gene in pigs.	1
348	SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.	310
347	The protein expression profile of ACE2 in human tissues.	35
346	The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2.	6
345	Comparative ACE2 variation and primate COVID-19 risk. 2020,	24
344	Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2.	2
343	Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2.	20
342	Low baseline pulmonary levels of cytotoxic lymphocytes as a predisposing risk factor for severe COVID-19. 2020,	3
341	Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19.	2
340	Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects.	2
339	Targeted Intracellular Degradation of SARS-CoV-2 RBD via Computationally-Optimized Peptide Fusions.	1
338	The SARS-CoV-2 receptor, Angiotensin converting enzyme 2 (ACE2) is required for human endometrial stromal cell decidualization. 2020,	7
337	The heterogeneous nature of the Coronavirus receptor, angiotensin-converting enzyme 2 (ACE2) in differentiating airway epithelia.	1
336	A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection.	9
335	ACE2 and SARS-CoV-2 Expression in the Normal and COVID-19 Pancreas.	4
334	Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells. 2020,	8
333	A computational approach to evaluate the combined effect of SARS-CoV-2 RBD mutations and ACE2 receptor genetic variants on infectivity: The COVID-19 host-pathogen nexus.	3
332	Physiology of cardiomyocyte injury in COVID-19. 2020,	4

331	SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients.	2
330	Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region.	6
329	Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease. 2002 , 67, 451-7	16
328	What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19. 2020 , 34, e13991	1
327	Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. 2006 , 116, 2218-25	260
326	Neurological consequences of COVID-19: what have we learned and where do we go from here?. 2020 , 17, 286	39
325	Impact of sex and gender on COVID-19 outcomes in Europe. 2020 , 11, 29	496
324	COVID-19 susceptibility: potential of ACE2 polymorphisms. 2020 , 21,	12
323	Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. 2013 , 8, e62833	70
322	The effects of angiotensin II and angiotensin-(1-7) in the rostral ventrolateral medulla of rats on stress-induced hypertension. 2013 , 8, e70976	29
321	Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. 2013 , 8, e71433	47
320	Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. 2014 , 9, e85958	42
319	Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. 2016 , 11, e0161760	10
318	Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. 2017 , 12, e0171975	8
317	Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. 2020 , 15, e0240647	17
316	Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. 2020 , 194, 1-8	10
315	The role of the renin-angiotensin system in the appearance and progression of renal cell carcinoma: a literature review. 2019 , 15, 143-149	1
314	COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. 2020 , 30, 688-699	11

313	ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. 2020 , 12, 6518-6535	49
312	Pathophysiology of SARS-CoV-2 infection in patients with intracerebral hemorrhage. 2020 , 12, 13791-13802	5
311	Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats. 2017 , 8, 20244-20251	8
310	Renin-angiotensin-aldosterone system in new coronavirus infection 2019. 2020 , 26, 240-247	7
309	Beneficial Effects of the Angiotensin-Converting Enzyme 2 Activator Dize in Renovascular Hypertension. 2019 , 26, 523-531	5
308	The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence. 2020 , 27, 463-475	13
307	The Renin Angiotensin System and Bipolar Disorder: A Systematic Review. 2020 , 27, 520-528	4
306	ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors. 2020 , 21, 892-901	8
305	ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke. 2013 , 11, 209-17	91
304	Angiotensin-converting Enzyme 2 roles in the Pathogenesis of COVID-19. 2020 ,	4
303	Many Faces of Renin-angiotensin System - Focus on Eye. 2017 , 11, 122-142	79
302	COVID-19 y su asociaci3n con los inhibidores de la enzima convertidora de angiotensina y los antagonistas de los receptores para angiotensina II. 2020 , 63, 30-34	2
301	ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review. 2020 , 9, 97-105	11
300	Perindoprilat changes ANG (1-9) production in renal arteries isolated from young spontaneously hypertensive rats after ANG I incubation. 2016 , 65, 561-570	1
299	The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. 2021 , 12, 627260	14
298	Bibliometric analysis of global scientific research on Coronavirus (COVID-19). 2020 , 34, 51	28
297	Angiotensin-converting enzyme 2. Approaches to pathogenetic therapy of COVID-19. 2020 , 97, 339-345	16
296	Effects on Cell Viability and on Apoptosis in Tumoral (MCF-7) and in Normal (MCF10A) Epithelial Breast Cells after Human Chorionic Gonadotropin and Derivated-Angiotensin Peptides Treatments. 2013 , 04, 65-69	2

295	Role of the renin angiotensin system in diabetic nephropathy. 2010 , 1, 141-5	63
294	COVID-19: Critical Role of Angiotensin 1-7 in ACE2 Modulation. 2020 , 49, 398-400	5
293	Ocular renin-angiotensin system with special reference in the anterior part of the eye. 2015 , 5, 110	2
292	ACE and ACE2 in kidney disease. 2015 , 4, 74-82	107
291	Comparative molecular docking analysis of the SARS CoV-2 Spike glycoprotein with the human ACE-2 receptors and thrombin. 2020 , 16, 532-538	3
290	Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS. 2020 , 12, e8411	5
289	Colonic expression of , the SARS-CoV-2 entry receptor, is suppressed by commensal human microbiota. 2021 , 13, 1984105	3
288	Respiratory epithelium: Place of entry and / or defense against SARS-CoV-2 virus. 2021 , 50, 35-43	
287	Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms. 2021 , 912, 174548	3
286	Mechanisms of SARS-CoV-2 entry into cells. 2021 ,	228
285	Review: Roles of human serum albumin in prediction, diagnoses and treatment of COVID-19. 2021 , 193, 948-955	15
284	The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.. 2021 , 14, 2705-2713	
283	Role of ACE2-Ang (1-7)-Mas axis in post-COVID-19 complications and its dietary modulation. 2021 , 477, 225	0
282	ACE2: a key modulator of the renin-angiotensin system and pregnancy. 2021 , 321, R833-R843	4
281	Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?. 2021 , 12, 725967	3
280	Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity. 2021 , 14, 1686-1692	2
279	Dipeptidases.	
278	Extracellular Matrix. 2005 , 191-214	

- 277 Angiotensin AT1 receptors Lula L
Hilenski, Kathy K Griendling, R Wayne Alexander. **2006**, 40-55
- 276 The Role of the Renin-Angiotensin System in Hepatic Fibrosis. **2007**, 113-134 1
- 275 Angiotensin-Converting Enzyme-2 (ACE2). **2007**, 1-4 1
- 274 Role of ACE, ACE2 and Neprilysin in the Kidney. **2007**, 1-20
- 273 Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1 α) and Angiotensin-Converting Enzyme 2. **2007**, 43-59 1
- 272 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54
- 271 Structure, Immunopathogenesis and Vaccines Against SARS Coronavirus. **2008**, 383-414
- 270 Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System. **2010**, 121-133
- 269 The Cell Biology of the SARS Coronavirus Receptor, Angiotensin-Converting Enzyme 2. **2010**, 23-30 2
- 268 Vitamin D, Renin, and Blood Pressure. **2010**, 937-953 1
- 267 Cardiovascular diseases under the action of occupational factors. **2010**, 2010, 71-81 1
- 266 Metalloproteases and Proteolytic Processing. **2011**, 457-482
- 265 angiotensin-converting enzyme 2 3.4.17.23. **2013**, 29-64
- 264 The ACE2/Ang-(1 α) Pathway in Cardiac Fibroblasts as a Potential Target for Cardiac Remodeling. **2013**, 547-557 1
- 263 OBESITY AND ANGIOTENSIN II. **2013**, 19, 196-203 1
- 262 Pharmacotherapy Considerations in Cardiovascular Disease in Women: Therapeutic Implications for Cardiovascular Disease. **2014**, 427-447
- 261 Anti-hypertensive Compounds in Miso.. **2015**, 110, 636-648
- 260 Renin-Angiotensin System. **2015**, 1-51

- 259 Mechanisms of the Renin Angiotensin System Influencing Atherosclerosis. 207-219
- 258 Renin-Angiotensin System. **2016**, 665-707
- 257 Liver. **2019**, 191-199
- 256 PROGNOSTIC VALUE OF COMORBIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY.
- 255 Trophic shift and the origin of birds.
- 254 Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality. **2021**, 11, 8
- 253 Downregulation of is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma. **2021**, 17, 5033-5044 0
- 252 COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. **2020**, 59, 207-225 0
- 251 Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. **2021**, 35, 22-32 2
- 250 COVID-19 and Renal Diseases: An Update. **2021**, 22, 52-67 8
- 249 Tropical Food Spices: A Promising Panacea for the Novel Coronavirus Disease (COVID-19). **2020**, 1, 347 2
- 248 An ongoing debate: Are the patients receiving angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers more susceptible to COVID-19 ?. **2020**, 25, 79-84
- 247 SARS-CoV-2 effect on male infertility and its possible pathophysiological mechanisms. **2021**, 9, e131 4
- 246 The role of angiotensin-converting-enzyme 2 receptor in SARS-CoV-2 infections, and new perspective for future therapies. A brief review on recent literature. **2020**, 9,
- 245 The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. 0
- 244 Levistilide A reverses rat hepatic fibrosis by suppressing angiotensin II-induced hepatic stellate cells activation. **2020**, 22, 2191-2198 1
- 243 Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulären System. **2006**, 377-407
- 242 Angiotensin II and Its Receptors in the Pathogenesis of Diabetic Nephropathy. **2006**, 3-21

- 241 Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic [Do We Have the Evidence?]. **2020**, 5, 105-109
- 240 Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. **2003**, 9, 57-62 20
- 239 Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. **2007**, 3, 125-37 71
- 238 The renin-angiotensin system and diabetes: an update. **2008**, 4, 787-803 88
- 237 Role of the angiotensin II receptor blocker valsartan in heart failure. **2001**, 6, 215-21 3
- 236 Postural orthostatic tachycardia syndrome: a dermatologic perspective and successful treatment with losartan. **2014**, 7, 41-7 8
- 235 Expression and cellular localization of the Mas receptor in the adult and developing mouse retina. **2014**, 20, 1443-55 13
- 234 Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators. **2020**, 36, 179-182 2
- 233 Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review. **2020**, 8, 337-340 0
- 232 Pharmacological approaches to the treatment of COVID-19 patients. **2020**, 6,
- 231 [Association of age distribution with the expression of angiotensin-converting enzyme 2 in lung tissues in severe acute respiratory syndrome coronavirus 2 infection: reflections from the study of RAS pathway expression in mice]. **2020**, 22, 1119-1124
- 230 [A review on the role of angiotensin-converting enzyme 2 in children with coronavirus disease 2019]. **2020**, 22, 1344-1348
- 229 Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. **2021**, 8, 54-60
- 228 Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients. **2021**, 142, 106934 2
- 227 Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. **2021**, 164, 69-82 8
- 226 Functional Effects of Cardiomyocyte Injury in COVID-19. **2021**, JVI0106321 4
- 225 Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19. **2021**, 12, 674074 4
- 224 Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It.. **2021**, 2021, 9293553 1

223	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. 2021 , 1, 233-258	1
222	Does COVID-19 Affect Adult Neurogenesis? A Neurochemical Perspective.	
221	The glycosylation in SARS-CoV-2 and its receptor ACE2. 2021 , 6, 396	13
220	Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19. 2021 , 22,	2
219	COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy. 2021 , 4, e440	3
218	Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients. 2021 ,	1
217	Moderate Intensity Aerobic Exercise Potential Favorable Effect Against COVID-19: The Role of Renin-Angiotensin System and Immunomodulatory Effects. 2021 , 12, 747200	3
216	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. 2021 , 12, 6791	9
215	SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases. 2021 , 14, 6191-6221	11
214	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. 2021 ,	0
213	Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19. 2021 , 27, 151	1
212	Obesity, A Risk Factor for Mortality in SARS CoV-2 Infection: A Narrative Systematic Review.	
211	Interactions amongst inflammation, renin-angiotensin-aldosterone and kallikrein-kinin systems: suggestive approaches for COVID-19 therapy.. 2021 , 27, e20200181	3
210	Insights Into the Role of Angiotensin-Converting Enzyme 2 in the Onset of Severe Acute Respiratory Syndrome Coronavirus 2 Pathogenesis. 2021 , 233-252	
209	Plausible Impacts of SARS-CoV-2 on Human Reproductive System. 2021 , 401-418	
208	Renoprotective Roles of Curcumin.. 2021 , 1328, 531-544	1
207	<i>>Morinda citrifolia</i></i> (Noni) Fruit Juice Inhibits SARS-CoV-2 Spike Protein Binding of Angiotensin-Converting Enzyme 2 (ACE2). 2021 , 09, 42-51	2
206	Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking.. 2021 , 301, 114424	3

205	Renin-Angiotensin-Aldosterone System. 2021,	0
204	Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. 2021, 8, 54-60	0
203	Damage to the Vascular Endothelium as a Leading Mechanism of COVID-19 Systemic Pathology. 2021, 11, 559-566	1
202	Cross-species virus transmission and its pandemic potential.. 2022, 46, 18	0
201	ACE2 Shedding and the Role in COVID-19.. 2021, 11, 789180	8
200	Intensive Care Unit-Acquired Weakness and the COVID-19 Pandemic: A Clinical Review.. 2022,	1
199	Prognostic Factors for COVID-19 Hospitalized Patients with Preexisting Type 2 Diabetes.. 2022, 2022, 9322332	0
198	Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy.. 2021, 12, 813012	2
197	Arterial Hypertension. 2022,	
196	Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19.. 2022, 12,	4
195	Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19.. 2022, 14,	2
194	Chronic Renin-Angiotensin System Activation Induced Neuroinflammation: Common Mechanisms Underlying Hypertension and Dementia?. 2021,	0
193	Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition.. 2022, 231, 114121	6
192	Diminazene aceturate, an angiotensin converting enzyme 2 (ACE2) activator, promotes cardioprotection in ischemia/reperfusion-induced cardiac injury.. 2022, 151, 170746	0
191	The Renin-Angiotensin System in COVID19. 2022, 133-153	
190	Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19.. 2022, 2022, 7423537	1
189	Are angiotensin converting enzyme (ACE1/ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A single-center cohort study.. 2022, 26, 133-140	0
188	Type 1 diabetes is associated with significant changes of ACE and ACE2 expression in peripheral blood mononuclear cells.. 2022,	1

187	Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2.. 2022 ,	1
186	Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation.. 2022 , 151, 170766	3
185	The dynamic nature of the coronavirus receptor, angiotensin-converting enzyme 2 (ACE2) in differentiating airway epithelia.. 2022 , 2, 100044	0
184	Renin-angiotensin system in normal pregnancy and in preeclampsia: A comprehensive review.. 2022 , 28, 15-20	0
183	Virtual Screening in Search for a Chemical Probe for Angiotensin-Converting Enzyme 2 (ACE2).. 2021 , 26,	0
182	Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. 2021 , 196, 105197	4
181	Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites.. 2021 , 11, 24336	2
180	Angiotensin Converting Enzyme 2 (ACE2) Expression in the Aged Brain and Visual System. 2021 , Vol 9,	
179	Molekularni mehanizam patogenog delovanja virusa SARS-CoV-2, uloga ACE2 receptora u generisanju surfaktanta i odr̃nju stabilnosti velikih funkcionalnih povr̃ha. 2021 , 46, 178-184	
178	Blood Pressure, Proteases and Inhibitors. 2022 ,	
177	Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. 2022 , 53, 51-76	1
176	Host polymorphisms and COVID-19 infection.. 2022 , 107, 41-77	1
175	[Role of ACE2 in COVID-19].. 2022 , 157, 115-118	
174	Diabetes, heart damage, and angiotensin II. What is the relationship link between them? A minireview.. 2022 , 56, 55-65	1
173	Relaci3 entre el sistema renina angiotensina aldosterona y las complicaciones cardiovasculares por SARS-CoV-2. 2022 , 67, 34-43	
172	Effects of Exercise Training on the Renin-Angiotensin System in the Kidneys of Dahl Salt-Sensitive Rats.. 2022 ,	0
171	The ACE2 Receptor for Coronavirus Entry Is Localized at Apical Cell-Cell Junctions of Epithelial Cells.. 2022 , 11,	2
170	Hypothesis: Emerging Roles for Aryl Hydrocarbon Receptor in Orchestrating CoV-2-Related Inflammation.. 2022 , 11,	0

- 169 Molecular and Physiological Aspects of SARS-CoV-2 Infection in Women and Pregnancy.. **2022**, 3, 756362
- 168 The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.. **2022**, 7, 57 1
- 167 Emerging complications of COVID-19 in a subset of Indian population: a pathological review with clinico-radiological case scenarios. **2022**, 53,
- 166 Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery.. **2022**, 8, e08957 0
- 165 mRNA expression of the severe acute respiratory syndrome-coronavirus 2 angiotensin-converting enzyme 2 receptor in the lung tissue of Wistar rats according to age.. **2022**, 15, 427-434
- 164 Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy.. **2022**, 3
- 163 Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells.. **2022**, 0
- 162 Theoretical Investigation of the Coronavirus SARS-CoV-2 (COVID-19) Infection Mechanism and Selectivity.. **2022**, 27,
- 161 Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate.. **2022**, 13, 868679 1
- 160 Effect of Calamintha officinalis on Vascular Contractility and Angiotensin-converting Enzyme-2.. **2022**,
- 159 Possible Beneficial Effects of Fresh Pomegranate Juice in SARS-CoV-2 Infection Conditions.. **2022**, 2022, 5134560
- 158 Crosstalk between SARS-CoV-2 Infection and Type II Diabetes.. **2022**, 0
- 157 Cannabidiol and SARS-CoV-2 Infection.. **2022**, 13, 870787 1
- 156 An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.. **2022**, 2
- 155 An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning cell survival and cardiovascular conditions in diabetic patients.. **2022**, 1 2
- 154 Dual role of the nasal microbiota in neurological diseases-An unignorable risk factor or a potential therapy carrier.. **2022**, 106189 0
- 153 ACE2 Receptor and Its Isoform Short-ACE2 Are Expressed on Human Spermatozoa.. **2022**, 23, 0
- 152 The role of membrane and circulating forms of ACE 2 in pathological processes in COVID-19 infection. **2022**, 27, 608-616

151	A Propensity Score-Matching Analysis of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Exposure on In-hospital Mortality in Patients with Acute Respiratory Failure.. 2022,	0
150	Differential transcriptomic landscapes of multiple organs from SARS-CoV-2 early infected rhesus macaques.. 2022, 1	1
149	Renin-angiotensin system (RAS) enzymes and placental trophoblast syncytialisation.. 2022, 547, 111609	2
148	Structural insights revealed by crystal structure of B38-CAP, an isoenzyme of carboxypeptidase ACE2, the receptor of SARS-CoV-2.. 2022, 606, 17-22	
147	Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms.. 2022, 20, 61-71	1
146	Role of angiotensin-converting enzyme 2 in fine particulate matter-induced acute lung injury.. 2022 , 153964	2
145	: Cell Surface-Inspired Universal Sensor for Betacoronaviruses.. 2022, 8, 22-42	6
144	Foe and friend in the COVID-19-associated acute kidney injury: an insight on intrarenal renin-angiotensin system.. 2022, 54, 1-11	
143	Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver.. 2021,	1
142	Angiotensin-Converting Enzyme 2 (ACE2) As a Novel Biorecognition Element in A Cell-Based Biosensor for the Ultra-Rapid, Ultra-Sensitive Detection of the SARS-CoV-2 S1 Spike Protein Antigen. 2021, 9, 341	0
141	Molecular Docking Approach of Natural Compound from Herbal Medicine in Java against Severe Acute Respiratory Syndrome Coronavirus-2 Receptor. 2021, 9, 1181-1186	2
140	The Effects of Angiotensin II or Angiotensin 1-7 on Rat Pial Microcirculation during Hypoperfusion and Reperfusion Injury: Role of Redox Stress.. 2021, 11,	
139	The Impact of and Gene Polymorphisms in Pulmonary Diseases Including COVID-19.. 2022, 36, 13-29	2
138	Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review.. 2021,	2
137	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours.. 2021, 9,	3
136	Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.. 2021, 19, e3001510	0
135	ACE2, BAT1, and SARS-CoV-2 spike protein: Structural and functional implications.. 2022, 74, 102388	0
134	An ACE2-Alamandine Axis Modulates the Cardiac Performance of the Goldfish via the NOS/NO System.. 2022, 11,	0

133	Nano-size Dependent Protein Corona Formation by SARS-CoV-2 Omicron Spike Protein Over Gold Nano-Colloid and Reversible Aggregation.. 2022 , 128967	0
132	Image_1.pdf. 2018 ,	
131	Data_Sheet_1.docx. 2020 ,	
130	Data_Sheet_1.ZIP. 2020 ,	
129	Table_1.DOCX. 2020 ,	
128	Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells.. 2022 ,	1
127	Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin. 2012 , 35, 378-83	8
126	SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review. 2022 , 10, 962	0
125	SARS-CoV-2 Susceptibility and Gene Variations Within Diverse Ethnic Backgrounds.. 2022 , 13, 888025	0
124	SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms. 2022 , 12,	1
123	From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?. 2022 , 13,	1
122	The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. 2022 , 106824	0
121	From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome).. 2022 ,	2
120	COVID-19 and cardiovascular disease: Manifestations, pathophysiology, vaccination, and long-term implication.. 2022 , 1-23	0
119	Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies. 2007 , 12, 639-650	12
118	Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases. 2022 , 58, 523-534	
117	Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.. 2022 , 23, 180	1
116	Impact of High-Dose Perindopril on Cardiac Function and Angiotensin Converting Enzyme 2/Ang-(1-9)/Ang-(1-7) in Rabbits with Ischemic Cardiac Dysfunction. 2022 , 12, 1558-1563	

115	ACE2 Decoy Receptor Generated by High-throughput Saturation Mutagenesis Efficiently Neutralizes SARS-CoV-2 and Its Prevalent Variants.. 2022 , 1-0	0
114	Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity. 2022 , 185, 1837-1839	4
113	The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: a literature review. 2022 , 23,	0
112	Protective neutralizing epitopes in SARS-CoV-2.	3
111	The key role of Calpain in COVID-19 as a therapeutic strategy.	1
110	Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication. 2022 , 23,	0
109	Association of underlying comorbidities and progression of COVID-19 infection amongst 2586 patients hospitalised in the National Capital Region of India: a retrospective cohort study.	
108	Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.	2
107	Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting. 2022 , 74, 462-505	1
106	Effects of the Hormonal Replacement Therapy with Estrogen and Progestins on the Vascular Renin-Angiotensin System of Ovariectomized Rats.	
105	Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.	0
104	Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. 2022 ,	4
103	Correlations between Kidney and Heart Function Bioindicators and the Expressions of Toll-Like, ACE2, and NRP-1 Receptors in COVID-19. 2022 , 10, 1106	0
102	A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection. 2022 , 12,	
101	SARS-CoV -2 spike protein enhances MAP4K3 / GLK -induced ACE2 stability in COVID -19.	1
100	Immunohistochemical expression of angiotensin-converting enzyme 2 in superficial and deep maxillofacial tissues: A cross-sectional study. 2022 , 5,	
99	Rational truncation, mutation, and halogenation of bradykinin neuropeptides as potent ACEII inhibitors by integrating molecular dynamics simulations, quantum mechanics calculations, and in vitro assays.	0
98	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. 2022 , 23, 8485	1

97	ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury. 2022 , 17, e0270920	
96	Role of aging in BloodBrain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19. 2022 , 19,	1
95	Co-existence and co-infection of influenza A viruses and coronaviruses: public health challenges. 2022 , 100306	0
94	ALAMANDINE: A PROMISING TREATMENT FOR FIBROSIS. 2022 , 170848	1
93	Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents.	1
92	Soluble ACE2 is Filtered into the Urine. 10.34067/KID.0001622022	0
91	Interactions between the intrarenal dopaminergic and the reninAngiotensin systems in the control of systemic arterial pressure. 2022 , 136, 1205-1227	0
90	Consequences of COVID-19 on the cardiovascular and renal systems. 2022 , 100, 31-38	0
89	Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. 2023 , 251, 123813	0
88	Sexual dimorphism in immune cell responses following stroke. 2022 , 172, 105836	2
87	Mechanism of action of drugs used in hypertension. 2023 , 349-367	0
86	The prognostic importance of the angiotensin II/angiotensin-(1 α) ratio in patients with SARS-CoV-2 infection. 2022 , 16, 175346662211225	0
85	Edema formation in congestive heart failure and the underlying mechanisms. 9,	1
84	The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences. 2022 , 14, 1906	0
83	Is Diminazene an Angiotensin-Converting Enzyme 2 (ACE2) Activator? Experimental Evidence and Implications. 2022 , 383, 149-156	0
82	Acute kidney injury and electrolyte disorders in COVID-19. 11, 283-292	0
81	An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV -2.	1
80	Sex Difference in MasR Expression and Functions in the Renal System. 2022 , 2022, 1-10	0

79	Effect of heated tobacco products and traditional cigarettes on pulmonary toxicity and SARS-CoV-2-induced lung injury. 2022 , 479, 153318	0
78	Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes.	0
77	Determination of soluble angiotensin-converting enzyme 2 in saliva samples and its association with nicotine. 2022 , 114443	0
76	ACE2 and LOX Enzyme Inhibitions of Different Lavender Essential Oils and Major Components Linalool and Camphor.	3
75	Evaluation of 68Ga- and 177Lu-Labeled HZ20 Angiotensin-Converting Enzyme 2-Targeting Peptides for Tumor-Specific Imaging.	0
74	Angiotensin converting enzyme (ACE) insertion / deletion (I/D) polymorphism and its association with cardiovascular adversities [A systematic review. 2022 , 201117	0
73	Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care. 2022 , 58, 1554	0
72	Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants. 2022 , 20, 657	1
71	Negative Effects of Chronic High Intake of Fructose on Lung Diseases. 2022 , 14, 4089	0
70	Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.	0
69	An Exploration of Nanoparticle-Based Diagnostic Approaches for Coronaviruses: SARS-CoV-2, SARS-CoV and MERS-CoV. 2022 , 12, 3550	0
68	An IgM-like Inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2.	0
67	On the essentiality of the angiotensin converting enzyme 2 receptor for SARS-CoV-2 infection and the potential of soluble angiotensin converting enzyme 2 proteins as universal approach for variants causing COVID-19. 2022 , 12,	1
66	Association of ACE2 Gene Variants with the Severity of COVID-19 Disease [A Prospective Observational Study. 2022 , 19, 12622	0
65	Analyzing the Impermeable Structure and Myriad of Antiviral Therapies for SARS-CoV-2. 2022 , 70, 80-84	0
64	Peptide inhibitors of angiotensin-I converting enzyme based on angiotensin (17) with selectivity for the C-terminal domain. 2022 , 129, 106204	0
63	Synergistic action of organophosphates and COVID-19 on inflammation, oxidative stress, and renin-angiotensin system can amplify the risk of cardiovascular maladies. 2022 , 456, 116267	0
62	Features of clinical manifestations, diagnosis, treatment and prevention of COVID-19 coronavirus infection in children. 2022 , 26, 15-27	0

61	Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches. 13,	○
60	Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) gene polymorphism with susceptibility to prostate cancer: an updated meta-analysis. 2022 , 20,	○
59	Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. 2023 , 208, 115370	○
58	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. 13,	○
57	The role of angiotensin I converting enzyme insertion/deletion polymorphism in the severity and outcomes of COVID-19 patients. 13,	○
56	Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection.	○
55	Circulating angiotensin converting enzyme 2 and COVID-19. 10, 12470-12483	○
54	COVID-19 and sex differences: role of estrogen. 2022 , 1, 120-128	○
53	A Closer Look at ACE2 Signaling Pathway and Processing during COVID-19 Infection: Identifying Possible Targets. 2023 , 11, 13	1
52	Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design. 2022 , 28, 3583-3591	1
51	DAD3 targets ACE2 to inhibit the MAPK and NF- κ B signalling pathways and protect against LPS-induced inflammation in bovine mammary epithelial cells. 2022 , 53,	○
50	Study of frequency and inheritance model of ACE1 I/D and ACE2 rs2285666 polymorphisms in COVID-19 patients with varying severity of lung involvement and its effect on serum cytokines levels.	○
49	What do we know about the renin angiotensin system and inflammatory bowel disease?. 1-13	○
48	Angiotensin-converting enzyme 2 in human plasma and lung tissue. 2023 , 32, 6-15	○
47	The Renin Angiotensin System at the Time of COVID-19. 2023 , 145-156	○
46	The role of calcium and calcium regulating hormonal system in the mechanisms of COVID-19 contagiousness and severity. 2022 , 14-22	○
45	Effectiveness of Hydroalcoholic Seed Extract of Securigera securidaca on Pancreatic Local Renin-Angiotensin System and Its Alternative Pathway in Streptozotocin-Induced Diabetic Animal Model. 2023 , 2023, 1-14	○
44	Relation of ACE2 with co-morbidity factors in SARS-CoV-2 pathogenicity.	○

43	Renin Angiotensin System and Thyroid Hormone Crosstalk: From Experimental Approaches to Clinical Perspectives. 2023 , 23-37	0
42	Emerging Role of ACE-2 in Cerebrovascular and Neurological Disorders: Lessons Learnt from COVID-19. 2023 , 431-447	0
41	Cardiovascular Protective Arm of Renin Angiotensin System. 2023 , 363-375	0
40	A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics.	0
39	Indoxyl Sulfate Promotes Metastatic Characteristics of Ovarian Cancer Cells via Aryl Hydrocarbon Receptor-Mediated Downregulation of the Mas Receptor. 2023 , 100025	0
38	Epigenetic modifications and regulation in infection. 2023 , 181-209	0
37	Unveiling the prevalence and impact of diabetes on COVID-19. 2023 , 287-301	0
36	Association between lung function and hypertension and home hypertension in a Japanese population: the Tohoku Medical Megabank Community-Based Cohort Study. Publish Ahead of Print,	0
35	Higher Angiotensin I Converting Enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.	0
34	Characterization of the First Animal Toxin Acting as an Antagonist on AT1 Receptor. 2023 , 24, 2330	1
33	ACE2 in pulmonary diseases. 2023 , 285-316	0
32	Angiotensin and COVID-19. 2023 , 473-489	0
31	Is the anti-aging effect of ACE2 due to its role in the renin-angiotensin system? Bindings from a comparison of the aging phenotypes of ACE2-deficient, Tsukuba hypertensive, and Mas-deficient mice	0
30	SARS-CoV-2 Angiotensin Converting Enzyme 2 (ACE2) Receptor Expression and Its Effects on COVID-19 Epidemiology in Children.	0
29	Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection. 2023 , 6, e202301969	0
28	Angiotensin-converting enzyme 2 at the heart of the COVID-19 pandemic. 2023 , 186, 906-922	0
27	Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease. 2023 , 13, 536	1
26	Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity. 2023 , 11, 510	0

- 25 The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. **2022**, 9, 17-32 ○
- 24 COVID-19 Biogenesis and Intracellular Transport. **2023**, 24, 4523 2
- 23 Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection. **2023**, 11, 612 ○
- 22 The renin-angiotensin system in the eye. **2023**, 419-447 ○
- 21 ACE2/angiotensin-(17)/mas receptor axis in the central nervous system. **2023**, 545-565 ○
- 20 Renin-angiotensin system and inflammation. **2023**, 77-105 ○
- 19 Transgenic animal models for the functional analysis of ACE2. **2023**, 491-503 ○
- 18 Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. **2023**, 13, 472 ○
- 17 The role of immune activation and antigen persistence in acute and long COVID. 108155892311580 ○
- 16 Prognostic value of elevated plasma angiotensin-converting enzyme 2 in cardiometabolic diseases: A review. **2023**, 102, e33251 ○
- 15 Sequelae of long COVID, known and unknown: A review of updated information. **2023**, ○
- 14 Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. ○
- 13 Comprehensive Bioinformatics analysis of angiotensin-converting enzyme 2 (ACE2). ○
- 12 Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?. 1-8 ○
- 11 Unraveling the Underlying Molecular Mechanism of Silent Hypoxia in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. **2023**, 12, 2445 ○
- 10 Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. **2023**, 24, 6253 ○
- 9 Arterial hypertension in COVID-19. **2023**, 101, 26-31 ○
- 8 SARS-CoV-2 Receptors and Their Involvement in Cell Infection. **2023**, 17, 1-11 ○

- 7 Molecular Understanding of ACE-2 and HLA-Conferred Differential Susceptibility to COVID-19: Host-Directed Insights Opening New Windows in COVID-19 Therapeutics. **2023**, 12, 2645
- 6 Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. **2023**, 6,
- 5 ACE and ACE2 catalytic activity in the fecal content along the gut.
- 4 Integrin α_5 is a key determinant of the expression of angiotensin-converting enzyme 2 (ACE2) in the kidney epithelial cells.. **2023**, 102, 151316
- 3 The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. **2023**, 14, 98-118
- 2 A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. **2023**, 13,
- 1 COVID-19 and Multiorgan Response: The Long-Term Impact. **2023**, 101756